Published in final edited form as:

Cell Mol Life Sci. 2011 February ; 68(3): 453–474. doi:10.1007/s00018-010-0468-6.

Interactions of the proteins of neuronal ceroid lipofuscinosis: clues to function

Amanda L. Getty and

Sanford Children's Health Research Center, Sanford Research USD, Sanford School of Medicine of the University of South Dakota, 2301 East 60th Street North, Sioux Falls, SD 57104-0589, USA. Department of Biochemistry and Biophysics, University of Rochester School of Medicine and Dentistry, Rochester, NY 14642, USA

David A. Pearce

Sanford Children's Health Research Center, Sanford Research USD, Sanford School of Medicine of the University of South Dakota, 2301 East 60th Street North, Sioux Falls, SD 57104-0589, USA. Department of Pediatrics, Sanford School of Medicine of the University of South Dakota, Sioux Falls, SD 57117, USA

David A. Pearce: David.Pearce@sanfordhealth.org

Abstract

Neuronal ceroid lipofuscinoses (NCL) are caused by mutations in eight different genes, are characterized by lysosomal accumulation of autofluorescent storage material, and result in a disease that causes degeneration of the central nervous system (CNS). Although functions are defined for some of the soluble proteins that are defective in NCL (cathepsin D, PPT1, and TPP1), the primary function of the other proteins defective in NCLs (CLN3, CLN5, CLN6, CLN7, and CLN8) remain poorly defined. Understanding the localization and network of interactions for these proteins can offer clues as to the function of the NCL proteins and also the pathways that will be disrupted in their absence. Here, we present a review of the current understanding of the localization, interactions, and function of the proteins associated with NCL.

Keywords

Batten disease; Lysosomal storage disorder

Introduction

Lysosomal storage disorders (LSD) are characterized by accumulation of storage material in lysosomes, and all LSD are caused by a protein deficiency due to genetic mutation in the corresponding gene (reviewed in [1]). While causative genetic mutations may be identified in many lysosomal storage disorders, the mechanism underlying why storage material accumulates often remains unclear. The neuronal ceroid lipofuscinoses (NCLs) are

characterized by accumulation of autofluorescent storage material and progressive neurodegeneration. NCLs are grouped by the gene that bears an autosomal recessively inherited genetic mutation and the onset of disease symptoms [2]. Mutations in eight genes have been identified that cause an NCL: *CLN1* (*PPT1*) in infantile (INCL), *CLN2* (*TPP1*) in late infantile (LINCL), *CLN3* in juvenile (JNCL), *CLN5* in Finnish variant LINCL, *CLN6* in variant LINCL, *CLN7* in variant LINCL or Turkish variant LINCL, *CLN8* in epilepsy with mental retardation (EPMR) or LINCL variants, and cathepsin D or *CTSD* (*CLN10*) in congenital-NCL. The incidence of NCL worldwide is 1 in 12,500 live births [2], and the most common NCL results from mutations in *CLN3*, causing JNCL (also known as Batten disease). The pathological progression of these diseases has been reviewed in [3, 4]. There is no cure, and treatments are limited to palliative care. Development of NCL treatments is limited by our narrow understanding of the disease.

Three forms of NCL are associated to mutations in soluble lysosomal proteins with known enzymatic function, namely: palmitoyl protein thioesterase-1 (PPT1), tripeptidyl peptidase-1 (TPP1), and cathepsin D (CTSD). Therefore, preclinical research is ongoing for enzyme replacement therapy [5, 6], gene therapy [7, 8], and stem cell therapy [9], which aims to functionally restore these missing enzymes. Conversely, the functions of the remaining proteins associated with NCL diseases are not fully characterized. *CLN5* is soluble, but *CLN3* and *CLN7* are integral membrane proteins, and each is trafficked to the lysosome. *CLN6* and *CLN8* are integral membrane proteins associated with the endoplasmic reticulum (ER). Despite these different localizations, dysfunction of any of these proteins results in characteristic autofluorescent storage material and a broadly similar, untreatable disease.

The accumulated storage material in NCL varies in composition, but is generally a combination of proteins, proteolipids, and metals [10]. A main component of the storage material that accumulates in the late-infantile variants and juvenile-NCL is subunit C of the mitochondrial ATP-synthase [11]; however, sphingolipid activating proteins (saposins A and D) are enriched in the infantile NCL (reviewed in [12]). Additionally, saposin D accumulates in congenital-NCL [13]. The heterogeneity of the storage material indicates that the accumulation of storage material may involve disruption of several pathways.

In the past decade, much work in the NCL field focused on small animal models of several of these proteins (reviewed in [4, 14]). However, the primary function of the many of the NCL proteins remains unknown. In this review, we explore the biochemistry of the NCL protein interaction network and its implication for NCL protein function.

NCL-associated soluble proteins in the lysosome

The most rapidly progressing NCL variants are associated with mutations in soluble lysosomal enzymes (Fig. 1a, Table 1). Deficiencies in these enzymes probably cause specific lack of digestion of metabolic substrates, which may contribute to lipofuscin accumulation directly. However, these complex diseases cause accumulation of heterogeneous mixtures of lipofuscin, which indicates that these proteins may be involved in elaborate pathways. While congenital-NCL, INCL, and LINCL are caused by loss of the specific enzymatic activities of CTSD, PPT1, and TPP1, endogenous substrates that are

critical for the development of NCL remain to be identified. CLN5, another soluble lysosomal protein with mutations that cause NCL, has unknown function. For each of these proteins, determining the critical function that is lost in NCL will be dramatically important for understanding not only NCL pathology, but also the fundamental role these proteins play in the lysosome and the cell.

Cathepsin D

Mutations in cathepsin D (*CTSD* or *CLN10*), a lysosomal aspartyl endopeptidase [15, 16], cause accumulation of autofluorescent storage material and neurodegeneration typical of NCL pathology, with very rapid progression causing death at or before birth [13, 17]. One patient with a LINCL-like progression of symptoms had two missense mutations in *CTSD* (W383C, F229I) causing defects in posttranslational processing and targeting to the lysosome of CTSD, as well as diminished enzyme activity [18]. Evidence for NCL pathology due to mutations or deletions of *CTSD* homologs has also been found in *Drosophila*, mice, sheep, and American bulldogs [19–21]. Severity of the phenotype seems to correlate with residual enzyme activity as point mutations in some patients [18], and American bulldogs [19] have a milder phenotype than mutations that result in inactivation or truncation of the protein, which result in congenital NCL pathology [13, 21]. *Ctsd*^{−/−} mice exhibit normal embryonic development, but postnatal apoptosis is seen in several tissues, including the retina and thymus, and mice die by postnatal day 26 with neuronal loss, autofluorescent storage material accumulation, astrogliosis and microglia activation, and intestinal necrosis and atrophy [22, 23]. Recently, the peripheral pathology of these mice was examined further by viral (AAV) vector-mediated gene transfer of *CTSD* either administered to the viscera or brain of the mice [24]. Only native AAV-*CTSD* injected into forebrains of *Ctsd*^{−/−} mice prolonged lifespan, prevented CNS pathology, and restored visceral organ integrity [24]. Enzyme activity was required to rescue these certain pathologies in *Ctsd*^{−/−} mice [24]. CTSD resides in the lysosome, but during certain conditions CTSD has been found to leak out of the lysosome or be secreted out of cells, such as neurons, which could explain the rescue of visceral pathology with forebrain injection of AAV-*CTSD* [24], and in certain cancers [25] reviewed in [16].

Though the optimum pH for CTSD activity is acidic, as in the lysosome, CTSD can cleave Tau at pH 7.0 indicating a potential involvement in Alzheimer's disease [26] or pro-apoptotic Bcl-2 protein Bid at pH 6.2, perhaps mediating apoptosis pathways directly [27]. CTSD has many proposed functions other than as an aspartyl endopeptidase, which may be pathologically relevant. The numerous substrates demonstrated for CTSD and accompanying proposed functions for CTSD have been reviewed in [16], but those potentially relevant for NCL disease will be discussed here.

CTSD undergoes post-translational processing during its maturation to the lysosome. In the ER, prepro-CTSD receives N-linked glycosylation on two asparagine residues, and then is transported to the Golgi for further processing and phosphorylation at position six of mannose residues. These mannose-6-phosphates (M6P) are recognized by mannose-6-phosphate receptors (MPR) that segregate lysosomal enzymes in the *trans*-Golgi network for transport to the en-dosomes and lysosomes. Once in the acidic environment of the lysosome,

the M6P-proenzyme-CTSD is dephosphorylated and activated by several cleavage events in the lysosome to form the mature aspartyl protease, CTSD (reviewed in [15]). CTSD has also been associated with the sortilin pathway and the sphingolipid activator precursor protein prosaposin, which indicate two MPR-independent sorting mechanisms for CTSD to the lysosome, where the acidic pH is optimum for CTSD enzymatic activity [15]. Because *Ctsd*^{-/-} mice develop normally prenatally, it was suggested that the loss of the endopeptidase activity of CTSD is compensated by other proteins [28]. However, CTSD may be essential for activation of specific regulatory pathways, substrates, growth factors or receptors that have not yet been identified as players in the generation of NCL pathology.

The role of CTSD in apoptosis has been debated [25]. CTSD is protective in retinal, thymus, and neuroblastoma cells [22, 23, 28, 29], but has pro-apoptotic characteristics as well (reviewed in [25]). During induced apoptosis, lysosomal CTSD is found in the cytosol due to lysosomal membrane permeabilization [30], where it can cleave Bid and perpetuate apoptosis cascades [27]; however, micro-injection of catalytically inactive CTSD exhibits the same effect on apoptosis, indicating that there may be undetermined protein interactions of CTSD in the cell [31]. Whether CTSD is a pro- or anti-apoptotic factor may be tightly regulated during certain specific cell contexts. In NCL pathology, CTSD function could be required for regulation of unidentified substrates in the neuron, or may function as a proapoptotic factor in its pro-enzyme or inactive form. Proenzyme CTSD levels were increased in sheep with a missense mutation in CTSD, which exhibited congenital NCL pathology [32]. Autophagic stress markers precede apoptosis in the brains of *Ctsd*^{-/-} mice, and alterations in phosphatidylinositol-3-kinase signaling, such as decrease in phosphorylation of Akt and GSK3 β at postnatal day 25–26 (P25–26), were shown [33]. It remains unclear what role CTSD directly plays in apoptosis pathways, but this role could contribute directly to the survival of neuronal populations in NCL.

In addition to alterations in phosphatidylinositol-3-kinase signaling, reduced CTSD levels cause disruptions in lipid homeostasis. Through positive modulation of ATP-binding cassette protein A1 (ABCA1), phospholipid and cholesterol efflux in macrophages and hepatocytes increases [34], showing that CTSD is involved in intracellular lipid trafficking and secretion. Further indicating that CTSD is involved in lipid homeostasis, CTSD protein levels are increased with Niemann-Pick type C1 (Npc1) inactivation in hepatocytes [35]. In the brain, it would be interesting to know if CTSD in glia has a similar effect, which could affect glial–neuron cell interactions. Loss of CTSD in the brain of *Ctsd*^{-/-} mice causes an increase or accumulation of bis(monoacylglycero)phosphate (BMP) and GM2/GM3 gangliosides in both neurons and glial cells, accompanied with impaired processing of prosaposin, a precursor to saposins A to D [36]. Myelination is also disrupted in *Ctsd*^{-/-} mice: significant decreases of three major myelin proteins (PLP, MBP, and CNP) have been demonstrated, significant thinning of axonal myelin sheets accompanied by axonal degeneration has been observed by EM, as well as hyper-myelination in subsets of neurons, and finally, mice do not survive past P26, a time of active myelination, which could indicate a delay in myelin assembly [37]. Accumulation of cholesteryl esters in the brain of P24 *Ctsd*^{-/-} mice also indicates that there is degradation of myelin in the brains of these

mice [36]. Taken together, cholesterol and lipid homeostasis and trafficking are disrupted in *Ctsd*^{-/-} mice.

It is clear that CTSD is an aspartyl endopeptidase; however, CTSD function affects multiple pathways in the cell beyond protein degradation in the lysosome. In NCL pathology, roles in apoptosis and lipid homeostasis are particularly relevant, and may be linked. Study of the disruptions in CTSD deficiency, which precipitate congenital-NCL, may reveal clues as to NCL pathways that are tangentially related by pathology.

PPT1

Palmitoylation is the addition of palmitate to cysteine through thioester linkage (S-acylation which tethers proteins to membranes, and this modification can be critical to certain recognition complexes for polarized protein trafficking (reviewed in [38]). Mutations in palmitoyl protein thioesterase (PPT1; *CLN1*) result in infantile-onset NCL (INCL) [39–43]. PPT1 was characterized as a thioesterase (Fig. 1a) based on its ability to depalmitoylate hRas in vitro [44]. The severity of INCL patient pathology correlates with residual PPT1 enzyme activity [45–47]; therefore, enzyme replacement gene therapy has been explored to treat INCL [48, 49]. The crystal structure of PPT1 revealed a soluble, globular monomer with an α/β hydrolase fold and a catalytic triad (S115, D233, H289) [50]. PPT1 is N-linked glycosylated at two asparagine residues (N197 and N232), which are required for PPT1 activity, transport to the lysosome through the MPR pathway, and prevention of degradation in the lysosome [50–53]; an additional glycosylation on N212 has also been described [54]. The most common mutations in PPT1 cause decreases in enzyme activity ($V_{\max}$), altered palmitate binding (K_m), and reduced levels of protein, which could reflect degradation of misfolded PPT1 in the ER [45]. Though the structure [50] and thioesterase activity of PPT1 [55] have been identified, we still do not understand PPT1's critical role that is lost in INCL.

PPT1 is a lysosomal protein [43]. Inhibitors of lysosomal proteins or of acidification of the lysosome, cause an accumulation of palmitoylated proteins that could be potential PPT1 substrates. This indicates that lysosomal proteolysis involves depalmitoylation of proteins, perhaps dependent on PPT1 activity [54]. The localization of PPT1 extends beyond the lysosome down neuronal axons and in synaptic compartments [52, 56–59]; however in one study, colocalization with synaptic vesicle markers was not observed in cortical neurons in culture [60]. Interestingly, processing and trafficking of PPT1 differs between non-neuronal and neuronal cell types [52]. In neurons, PPT1 transport differs from lysosomal aspartylglucosaminidase (AGA), which goes directly to perinuclear vesicles, while PPT1 is endocytosed from the cell surface and maintains a diffuse localization, by antibody uptake assay [52]. Therefore, PPT1 may have distinct functions in neurons, reflected by unique roles for palmitoylation in neuronal function.

Palmitoylation is reversible and is particularly important in neuronal regulation and function. For example, palmitoylation is required in the targeting of synaptic proteins involved in neurotransmission: synaptosomal-associated protein-25 (SNAP25), glutamic acid decarboxylase-65 (GAD65), neural cell adhesion molecule (NCAM), and post-synaptic density-95 (PSD95, (reviewed in [38]). These proteins require depalmitoylation for vesicular trafficking, and thus PPT1 deficiency would cause these proteins to maintain anchorage in

the membrane, preventing recycling of synaptic vesicle components. A progressive loss of the releasable synaptic vesicle pool was observed in cultured *Ppt1*^{-/-} cortical neurons and aging *Ppt1*^{-/-} mouse brains over time [59, 60]. This was observed as a reduction of depalmitoylated proteins (VAMP2, SNAP25, syntaxin 1) in the soluble fractions of synaptosomes, indicating that these proteins remained anchored in the membrane. A reduction in the number of synaptic vesicles at nerve terminals as observed by transmission electron microscopy also indicates that PPT1 deficiency prevents normal synaptic vesicle recycling following release of neuro-transmitters at the presynaptic terminal [59, 60]. PPT1 clearly has important roles in synapse integrity, which may contribute to neurodegeneration in INCL.

PPT1 deficiency results in accumulation of autofluorescent storage material that is enriched with saposins A and D in INCL pathology [61]. Lipid oxidation induced apoptosis was initially suggested as a mechanism of cell death in PPT1 deficiency [54]. Cells with PPT1 deficiency exhibit elevated markers for oxidative and ER stress and activation of the unfolded protein response (UPR), with accompanied induction of apoptosis [62–65]. Specifically, caspase-4, caspase 9, and caspase-12 levels are increased in PPT1-deficient cells, which are accompanied by increases in detectable reactive oxygen species (ROS), superoxide dismutase (SOD1), and cleaved PARP [62, 63]. Increased levels of S-acylated proteins are also found in the ER of PPT1 deficient cells, which could activate UPR [65]. Sensitivity to ER stress conditions is not unique to INCL, but has been found associated to other LSD [66], indicating a connection between the lysosome and the ER, and between PPT1 and oxidative stress-mediated apoptosis. In INCL, ER stress may reflect accumulation of unfolded proteins that are trafficked back to the ER due to lysosomal dysfunction, rather than a direct role of PPT1 in mediating apoptosis [64]. Alternatively, PPT1-deficient cells were resistant to TNF α -induced apoptosis, showing a reduced amount of cleaved caspase-9, cleaved caspase-3, Bid, or a decrease in cytochrome C release when treated with TNF α [66]. This insensitivity was not found in cells deficient for other NCL proteins (CLN3 or CLN5), and may indicate that regulation of protein palmitoylation is important for propagation of apoptosis pathways. A requirement for palmitoylation on the TNF α -receptor in order for receptor internalization was proposed, which directly could explain the insensitivity of PPT1-deficient cells to TNF α , but this was not shown experimentally [66]. Thus, PPT1-deficient cells exhibit an increased level of oxidative and ER stress, but are insensitive to TNF α -mediated apoptosis.

Increased ER stress will cause release of ROS and Ca²⁺ from the ER, which could contribute to neurodegeneration. Specifically in the cerebellum of *Ppt1*^{-/-} mice, there is Purkinje cell loss, reactive gliosis, granule cell apoptosis, microglia activation, and demyelination [67]. Transcript profiling of *Ppt1*^{-/-} mouse brains indicated upregulation of genes involved in cholesterol metabolism, neuronal maturation, and calcium homeostasis, i.e. significant increases in α -synuclein [68]. These alterations are supported by a gene modifier screen completed in *Drosophila* linking PPT1 with genes involved in synaptic vesicle recycling, endosomal trafficking, and synaptic development [69, 70]. Cholesterol metabolism was confirmed to be altered in *Ppt1*^{-/-} neurons both by upregulation of the rate of sterol synthesis [68] and by an increased uptake of apolipoprotein A-1 (apoA-I) [71].

Together, these studies indicate a potential dysfunction of neuronal–glia cell interactions during neuronal maturation and synaptogenesis in the developing PPT1-deficient brain [71].

Despite numerous studies describing PPT1 involvement in many linked pathways, it is still unclear what key substrates of PPT1 are not processed during PPT1 deficiency. The *in vivo* substrates and interactions of PPT1 must be known in non-neuronal and neuronal cells in order to fully understand PPT1 and therefore treat INCL effectively. Initially, PPT1 was not found to interact with any other proteins by yeast-2-hybrid [72]; however, numerous interactions of PPT1 have been described recently. Purified PPT1 secreted from CHO cells was found to interact with the F₁-complex of the ATP synthase by GST-pull-down and surface plasmon resonance [71]. PPT1 deficiency correlated with alterations in the amount of F₁-subunits in the neuronal plasma membrane by total internal reflection fluorescence microscopy (TIRF); however, colocalization of PPT1 and β -subunit of the F₁-complex in neurons or fibroblasts has not been reported, bringing into question whether interaction between these two proteins would occur in the cell [71].

TPP1

Late-infantile NCL (LINCL) is caused by mutations in tripeptidyl peptidase-1 (TPP1; CLN2) [73–75] (reviewed in [76]). TPP1 is a lysosomal serine protease with N-terminal exopeptidase activity, weak endoproteolytic activity, [77, 78] and known structure [79, 80] (reviewed in [76]) (Fig. 1a). It is the only known eukaryotic member of the sedolisin family of carboxy-peptidases, by homology [81]. TPP1 is glycosylated on several residues, but N-glycosylation of Asn-286 is required for activity and maturation through the MPR pathway to the lysosome [80, 82–84]. In the lysosome, it undergoes autocatalytic cleavage for activation at acidic pH [78]. Interestingly, recent evidence suggests the cleaved prosegment (176 aa) is a slow-binding inhibitor of TPP1, and prosegment binding also slows the rate of TPP1 inactivation at neutral pH [85]. Prosegment binding to TPP1 outside of the lysosome could permit activity at alkaline pH, in other regions of the cell; however, TPP1 activity has been examined mostly *in vitro*. In cultured hippocampal neurons, TPP1 is contained in lysosomes, shown by colocalization with lysosomal membrane protein, LAMP1, and is not found in synaptophysin-positive synaptic vesicles in neurons [86].

TPP1 activity is lost in the brain, liver, kidney, heart, and intestine of LINCL patients and the expression of TPP1 is developmentally controlled, reaching peak expression at the same age as the initial age of symptoms onset (2–4 years) [87]. Residual TPP1 protein activity can be detected by histology in certain patients, which may correlate with protracted phenotype [87, 88]. TPP1's endogenous preferred substrates are unclear, but TPP1 has activity on angiotensin-I and -II [89], cholecystokinin [90], neuropeptide neuromedin B [91], Bid during apoptosis [92], and the mitochondrial ATP-synthase subunit C, which is a major component of the storage material accumulated in LINCL [93]. TPP1 likely has numerous protein substrates, and highest efficiency cleavage for Arg-Ala-Gly peptides has been specifically shown [94] (reviewed in [76]). Activity of TPP1 was increased in *CLN5*^{−/−} patient fibroblasts, which could indicate a common disruption or link between the two proteins [95]. Recently, TPP1 expressed with patient missense mutations in CHO cells exhibited low activity and multiple routes of clearance, with some following the ubiquitin/

proteasome system and others being hyper-secreted, indicating that misfolding may contribute to the dysfunction of mutated TPP1 [96]. Loss of TPP1 activity contributes to the accumulation of products in the lysosome, and residual activity in mutated TPP1 can alter LINCL pathology [88]; however, the storage material that accumulates in LINCL patients is complex.

Like PPT1, TPP1-deficient cells are resistant to TNF α -induced apoptosis, which may indicate a link between these two proteins or lysosomal involvement in the perpetuation of apoptotic signaling pathways in general [92]. TPP1 has been reported to interact with NCL proteins, which will be discussed later. The role that TPP1 plays outside the lysosome or on specific substrates has not been fully characterized, but identification of *in vivo* substrates, interacting partners, or primary functions of TPP1 in neurons would aid in our understanding of LINCL pathology.

CLN5

The function of CLN5, the protein mutated in Finnish variant late infantile NCL (FinLINCL), is currently unknown (Fig. 1c). CLN5 is a 407 amino acid protein with a predicted molecular weight of 46 kDa [97]. Four in-frame alternative initiator codons for CLN5 have been examined at Met-1, Met-30, Met-50, and Met-62 [97], which can produce polypeptides of molecular weights of 46.3, 43.4, 41.5, and 40.3 kDa; and all have been seen in reticulate cell-free translation systems, *in vitro* [95, 98]. In a recent study, CLN5 was tagged on the N-terminus with GFP to determine if the predicted signal sequence on the N-terminus is cleaved [99]. Using a new CLN5 antibody directed at the C-terminus of CLN5, cleavage of the N-terminus of overexpressed CLN5 in COS-1 cells was confirmed for all four variants of CLN5 [99], which indicates that several forms of CLN5 may exist in perhaps different cell types or regulatory conditions.

CLN5 was originally described to have two transmembrane domains, as predicted by BCM Transmembrane Prediction Program and by Kyte and Doolittle hydrophobicity plot analysis [97]; however, the solubility of CLN5 has been debated [98, 100]. CLN5 is most likely a soluble protein based on the presence of CLN5 in culture medium due to secretion from transiently transfected BHK-21 cells [98], the ability to isolate CLN5 by mannose-6-phosphate affinity purification [101], and the likelihood that a N-terminal signal peptide is cleaved from CLN5 in its maturation to the lysosome [98, 102]. Further, both mouse and human CLN5 were reported to be soluble by Triton X-114 fractionation with the appropriate controls, using PDI (a soluble protein) and transferrin receptor (a membrane protein) for confirmation [100]. CLN5 is highly glycosylated at up to eight sites (Fig. 1c), resulting in an observed size of 60–80 kDa (Table 1) [95, 98], and glycosylations are both sensitive to EndoH (highly complex or mannose type sugars) and PNGaseF (N-type linked) treatments, indicating complex glycosylations [95, 98, 99]. Mouse CLN5 was confirmed to contain three mannose-6-phosphate (M6P) residues making it likely that CLN5 follows the MPR pathway to the lysosome [103], but in MPR deficient fibroblasts, CLN5 was found in LAMP1⁺ vesicles [99], indicating that CLN5 may use alternate routes to the lysosome.

CLN5 predominantly colocalizes with lysosomal associated membrane protein-1 (LAMP1) in several studies [95, 98–102, 104–106]. Mutations in *CLN5* result in Finnish variant late

infantile NCL (Fin-vLINCL) [97, 107, 108]; recently, mutations in CLN5 have been found outside Finnish populations [97, 102, 106, 109, 110]. Pathogenic mutations seem to cause retention of CLN5 in the ER/Golgi, in immunocytochemistry of cells overexpressing mutated CLN5 [98, 99, 102]. The presence of complex glycosylations on several mutated forms of the CLN5 proteins, such as the major Finnish mutation (Trp392Stop), indicates that at least partial populations of the mutated proteins leave the ER to the Golgi apparatus for glyco-sylation [95]. In summary, evidence suggests that CLN5 is synthesized at one or all of four initiator codons, depending on condition or cell type, as a preproprotein. In the ER, the N-terminal signal peptide is cleaved, and the protein receives mannose-type sugars, at which point it is trafficked to the Golgi apparatus for additional glycosylation and modification to the mature 50 kDa form. The mature form then completes its journey to the lysosomes through either the MPR or secretory pathway [99].

Several interactions of CLN5 with other NCL proteins have been described [95] and will be discussed in a later section. Perhaps due to the extensive post-translational modifications of CLN5, there are several caveats with studies of this protein. Antibodies generated to CLN5 do not recognize the endogenous CLN5, and therefore can only be used on overexpressed protein [95, 98, 102]. All these studies are done in overexpression systems in COS-1 or BHK cells, which provide valuable information, but the data must be examined with the caveat that, at endogenously regulated levels, subtle variations and treatments of this important CLN5 protein may be missed. It is clear that CLN5 has important functions due to the pathology that results from its loss, but the function remains elusive. Due to massive glycosylations, it is possible that it may be a sensor important in trafficking or integrity of lysosomes, but we have no evidence yet to suggest the role it plays in lysosomes or neurons.

NCL-associated membrane proteins

Mutations in four distinct transmembrane proteins are associated with an NCL disease (Fig. 1b, d, e), each encoded separately with no clear homology to other proteins. CLN3 and CLN7 are found in the lysosome, while CLN6 and CLN8 are localized to the ER, but dysfunction in each causes lysosomal storage accumulation. The primary function of each membrane protein associated with NCL disease is unknown. Much of what we have learned thus far about these proteins has come from loss of function models such as yeast and mice constructed to lack these proteins. Not surprisingly, studying the effect of protein loss has implicated each protein in several biological pathways. Studies focused on elucidating interaction partners should reveal more detail as to the precise function of these hard to study proteins. Due to similar disease pathology, direct interactions between the NCL proteins have been proposed by several studies; however, as we detail later in this review, participation in a common pathway is unlikely.

The interaction network of CLN3

Mutations in *CLN3* result in the most common NCL: juvenile-onset NCL (JNCL) [2, 111]. The most common mutation in patients is a frameshift mutation after amino acid Cys-153, which results in the addition of 28 novel amino acids and a termination stop codon [111]. While some debate continues concerning the possibility of residual function being retained by this predicted truncated protein product, it appears that the mRNA transcripts are

degraded, resulting in an absence of CLN3 protein and a complete loss of CLN3 function [112]. Despite a decade of research into the primary cause of JNCL, the function of CLN3 remains unknown. Following the characterization of CLN3 topology, localization, and posttranslational modifications, protein interacting partners have been examined to determine the endogenous function of CLN3 (Table 1). CLN3 has been reported to be present in the nucleus [113], Golgi [114–116], mitochondria [117], plasma membrane [113], endosomes and lysosomes [114, 115, 118, 119], neuronal processes and synaptosomes [120, 121]. The localization experiments were conducted using several techniques and have been completed with different CLN3 antibodies, expression constructs, epitope tags, and cell types. The validity of these localization studies has been critically reviewed in [122].

In mammalian cells, CLN3 has most often been localized to the endosome and lysosome, and for the purpose of this review, this localization will be considered the primary location of CLN3 [118, 119, 123–125]. CLN3 is expressed at very low endogenous levels and is a highly hydrophobic protein, which has made generating an antibody for studying CLN3 localization and function difficult. Peptide-derived polyclonal antibodies are used most frequently to study CLN3, reviewed in [122], however, in only one study has the specificity of the CLN3 antibody been truly verified [118]. Experimentally, CLN3 has six transmembrane domains with both termini facing into the cytoplasm (Fig. 1b); though a five membrane domain topology has also been suggested [118, 122, 125–128]. Using site-directed mutagenesis, loss of CLN3 glycosylation had no effect on the localization of CLN3, but loss of C-terminal farnesylation caused an enrichment of CLN3 at the cell surface [119], indicating the importance of this modification for localization of CLN3. One interpretation for multiple localizations of CLN3 may be that this protein has functions in multiple regions of the cell, or perhaps even that CLN3 has a specific or conditional function in certain cell types. However, CLN3 most likely functions at the lysosome, but has transient roles in dynamic vesicles that interact with lysosomes at specific regions in the cell during specific conditions. CLN3 has been reported to interact with several proteins (Fig. 1b), which further indicates that it is a multifunctional protein and suggests that at certain times some of the cellular pool of CLN3 might have alternate localizations.

A common technique used to determine protein interaction partners is yeast-2-hybrid (Y2H), which has been employed to identify interacting partners of CLN3 in several studies [129]. The classic technique requires fusion proteins to enter the nucleus to initiate reporter gene expression, which is not ideal for assaying highly hydrophobic proteins, such as the NCL membrane proteins. An alternate Y2H, the CytoTrap (Stratagene), interactions occur in the cytosol and associated with the plasma membrane, rather than in the nucleus. The disadvantage of both methods is identification of false positive interactions; therefore, all candidates must be validated by co-immunoprecipitation and colocalization in mammalian cells, which are limited by poor antibody reagents for NCL proteins. Additionally, screening transmembrane proteins in Y2H systems is challenging, so many studies screened the hydrophilic regions of the proteins that would be exposed to the cytosol or lumen of an organelle, rather than full-length proteins. All interactions of CLN3 were initially identified using Y2H, and these interactions have revealed a complex interaction network for CLN3 throughout the cell, each of which will be discussed.

CLN3 was shown to interact with the cytoskeletal protein β -fodrin and the $\text{Na}^+\text{-K}^+\text{-ATPase}$ complex (Fig. 1b) [130]. Based on the six-transmembrane domain topology, the N-terminus and the second cytoplasmic loop of CLN3 were screened for interactions using the *LacZ* β -galactosidase Y2H [130]. The interactions were validated by immunoprecipitation of overexpressed CLN3 and endogenous candidate interactors from COS-1 cell extracts, using CLN3 antibodies [130]. It was shown that CLN3 co-immunoprecipitated with subunits of the $\text{Na}^+\text{-K}^+\text{-ATPase}$ and fodrin (β -II-spectrin chain), but it is not clear which protein CLN3 interacts with directly, or if the three proteins interact in a complex. Fodrin is a heterotetrameric complex of two α and two β chains that binds the plasma membrane through pleckstrin homology (PH) domains and tethers membrane protein complexes to the actin cytoskeleton [131, 132]. The spectrin-ankryin-actin skeleton at the plasma membrane maintains and stabilizes the polarization of proteins (reviewed in [132]). CLN3 may be trafficked to the lysosome through the adaptor protein-1 and -3 (AP-1 and AP-3) complexes binding CLN3 dileucine lysosomal sorting motifs, and loss of these motifs resulted in CLN3 enriched in the plasma membrane [123–125, 127]. CLN3 would be capable of interacting with plasma membrane proteins during a trafficking pathway that reached the plasma membrane on the way to the lysosome, or it could interact within lysosomes close to the plasma membrane. Distribution of fodrin architecture in JNCL fibroblasts and *Cln3*^{-/-} mouse brain sections was altered [130], and these changes indicate a possible role for CLN3 in this structure either in the plasma membrane, or perhaps in a special function in neurons. Synapsin-1 interacts with fodrin (β -spectrin) at the synapse and synaptic transmission of hippocampal neurons was blocked in vitro by treatment with antibodies to β -spectrin, thus fodrin complexes may have unique roles in neurons [133]. Fodrin controls cell surface distribution of the $\text{Na}^+\text{-K}^+\text{-ATPase}$ directly in polarized cells such as Madin-Darby canine kidney (MDCK) cells [134] and in the inner segment of rod photoreceptors [135]; therefore, at the plasma membrane these two interacting partners of CLN3 probably interact as a multi-protein complex.

The $\text{Na}^+\text{-K}^+\text{-ATPase}$ maintains chemical gradients at the cell surface by pumping Na^+ out and K^+ into the cell [136], and its function is integral to neuronal function. The $\text{Na}^+\text{-K}^+\text{-ATPase}$ exists in several isoforms, based on heterogenic combinations of α , β subunits, and FXYD regulatory proteins, with tissue and region-specificity (reviewed in [137–139]). CLN3 interacts with the ubiquitously expressed $\alpha_1\text{-}\beta_1$ isoform by co-immunoprecipitation from COS-1 cells, using CLN3 antibodies and antibodies to endogenous $\alpha_1\text{-}\beta_1$ subunits [130]. There is no defect in the ion pumping activity of $\text{Na}^+\text{-K}^+\text{-ATPase}$ in *Cln3*^{-/-} neurons; however, the dynamic trafficking of the $\text{Na}^+\text{-K}^+\text{-ATPase}$ at the plasma membrane is altered in *Cln3*^{-/-} [130]. By total internal reflection fluorescence (TIRF) microscopy, the neuron-specific $\alpha_3\text{-}\beta_1$ isoform was increased at the plasma membrane in *Cln3*^{-/-} neurons [130]. Ouabain treatment inhibits the $\text{Na}^+\text{-K}^+\text{-ATPase}$ and induces its internalization from the plasma membrane, and following ouabain treatment, internalization of $\text{Na}^+\text{-K}^+\text{-ATPase}$ was decreased in *Cln3*^{-/-} neurons [130]. Defects in endocytosis due to CLN3 loss were examined in another study because of a weak interaction between CLN3 and Hook1 [140], a microtubule binding protein involved in endocytosis [141–143]. The rate of transferrin receptor uptake from the cell surface by endocytosis was not altered by CLN3 deficiency; however, the recycling of the receptor back to the plasma membrane was increased in JNCL

fibroblasts [140]. Importantly, further investigation of Hook1's interaction with Ankyrin-G at the spectrin-Ankyrin-actin cytoskeleton in *Cln3*^{-/-} mice revealed no defects [144]. Therefore, it does not appear that CLN3 is directly involved in general endocytosis pathways for internalization of the transferrin receptor, or perhaps the Na⁺-K⁺-ATPase subunits. Therefore, the increased Na⁺-K⁺-ATPase subunits at the plasma membrane of *Cln3*^{-/-} neurons may reflect an indirect consequence of CLN3 loss. The association of fodrin and the Na⁺-K⁺-ATPase in *Cln3*^{-/-} was not examined directly, but alterations in fodrin and Na⁺-K⁺-ATPase subunit distribution in *Cln3*^{-/-} neurons and JNCL fibroblasts indicate that CLN3 could be required for Na⁺-K⁺-ATPase turnover at the plasma membrane in a tethering, structural, or trafficking role.

Beyond functions in ion homeostasis, the Na⁺-K⁺-ATPase has functions in cell polarity, adhesion, endocytosis, and in mediating calcium oscillations (reviewed in [145]). Importantly, glutamate-mediated neurotransmission requires coupling of glutamate transporters and the Na⁺-K⁺-ATPase to drive both transport and maintenance of the chemical gradient, either directly through Na⁺-K⁺-ATPase and glutamate transporter protein complexes [146], and also through Na⁺-K⁺-ATPase activity regulated AMPA receptor turnover in neurons [147]. Cerebellar granule cell neurons from *Cln3*^{-/-} mice exhibit increased sensitivity to AMPA-mediated excitotoxicity [148] accompanied by an increase in glutamate in JNCL patients [149]. CLN3 has been found in the synaptosomal compartment [120, 150], and it would be interesting to know if endogenous CLN3 interacts with fodrin and the Na⁺-K⁺-ATPase down axonal projections of neurons. If the absence of CLN3 causes dysregulation of fodrin-Na⁺-K⁺-ATPase complex dynamics and turnover, it could contribute to previously recognized pathology in *Cln3*^{-/-} or JNCL through modulation of ion homeostasis in neurons during synaptic transmission and in neuronal excitotoxicity.

Electrochemical gradients drive neuronal excitation and synaptic transmission, therefore ion homeostasis in neurons is particularly well regulated. Calcium cations (Ca²⁺) are involved in many signaling pathways in all cells, and are required for presynaptic transmission in neurons. Calsenilin is a multi-functional Ca²⁺-dependent protein that interacts with presenilin proteins and modulates amyloid β -peptide (A β), acts as a transcriptional repressor (DREAM), and binds the N-terminus of Kv4 α -subunits of A-type voltage-gated K⁺ channels (KChIP3) [151–156]. This protein is encoded by a single gene, but clearly calsenilin/KChIP3/DREAM (hereafter referred to as calsenilin) is involved in different functions which may be mediated through localization and protein binding partners [157]. Using a Y2H screen to identify calsenilin interaction partners, calsenilin was found to interact with the C-terminus of CLN3 (amino acids 385–438) [158], and this interaction was further confirmed by immunoprecipitation. Calsenilin binds Ca²⁺ through its EF-hand domains, [159] and although CLN3 has not been shown to directly bind Ca²⁺ or EF-hand domains, increasing Ca²⁺ concentration in vitro and in cells decreases the CLN3-calsenilin affiliation in a concentration-dependent manner [158]. Calsenilin modulates neuronal sensitivity to Ca²⁺ transients in a pro-apoptotic manner, and therefore mediates Ca²⁺ toxicity [153]. Overexpression of CLN3 in SH-SY5Y cells led to protection from Ca²⁺-mediated apoptosis and calsenilin expression was reduced in this same overexpression system, indicating a strong interplay between these two proteins [158]. Calsenilin binding to Kv4

subunits of A-type voltage-gated K^+ channels dramatically affects localization and posttranslational modifications of channel subunits, and members of the KChIP family bind to Kv4 subunits in a tightly controlled and nonredundant manner [160]. An interaction between calsenilin and CLN3 could be caused by co-trafficking of CLN3 with channels to specific cell regions, such as at the cell periphery where binding could be responsive to Ca^{2+} transients.

A-type voltage-gated potassium channels and their interacting proteins modulate the excitation and repolarization of both neurons and myocytes [161, 162]. In *Cln3*^{-/-} mice, neurons are selectively sensitive to AMPA-mediated excitotoxicity, and the loss of the interaction between calsenilin and CLN3 may contribute to this neuron response [148]. Recently, researchers proposed a new pathway for astrocyte differentiation involving the pituitary adenylate cyclase-activating polypeptide (PACAP)-cAMP- Ca^{2+} -calsenilin cascade because of the increased numbers of astrocytes and neurons in *Calsenilin*^{-/-} mice [163]. Increased astrocytosis and gliosis are characteristic of *Cln3*^{-/-} mice [164] as well, and it is tempting to consider if the loss of the CLN3-calsenilin interaction could contribute to that pathology. Calsenilin was initially identified as an interactor of presenilins, which combine with nicastrin, APH-1, and presenilin enhancer-2 (PEN-2) to compose the γ -secretase complex [152, 165]. The γ -secretase complex cleaves single-pass transmembrane proteins at the plasma membrane, such as amyloid precursor protein (APP) and Notch, and though calsenilin is not required for catalysis, A β peptides were decreased in *Calsenilin*^{-/-} mice, linking calsenilin with γ -secretase function [166]. Notch mediates cell-cell communication in numerous processes, such as development and function of neurons [167]. Examination of the cerebellum of *Cln3*^{-/-} mice revealed an increase in Notch2 expression and thinning of the internal granule cell layer (IGL), accompanied by increased number of proliferating cells (BrdU+) in *Cln3*^{-/-} cerebellum [168]. In the developing cerebellum, granule neuron precursors (GNP) proliferate in the external granule cell layer (EGL), then differentiate and migrate to the IGL; and Notch signaling contributes to the fate decisions of proliferating or differentiating GNP cells [169]. If CLN3 and calsenilin interact close to the cell periphery in order to regulate Ca^{2+} transients in response to either A-type voltage-gated potassium channel ion flux, or to regulate γ -secretase localization or activity, then these pathways would be disrupted with CLN3 dysfunction.

In *Drosophila*, genetic interactions of *CLN3* with the Notch and Jun N-terminal kinase (JNK) signaling pathways were observed; specifically, overexpression of CLN3 caused decreased Notch signaling and activated JNK signaling [170]. Interestingly, CLN3 overexpression had no effect on Notch protein expression levels or downstream signaling capability, which was shown by co-expression of cleaved Notch with CLN3; therefore, the cause of Notch-like phenotypes were most likely due to alterations in the Notch protein function itself [170]. The authors suggested that overexpression of CLN3 altered the cleavage or processing of Notch in certain cell types or developmental periods [170]; however, the cleavage of Notch was not directly assayed. If CLN3 overexpression caused an increased association with calsenilin, alterations in the γ -secretase complex presenilin levels may result, causing altered cleavage of Notch at the plasma membrane in these specific cell types. At this time, calsenilin's numerous functions in the cell are still being elucidated, and

CLN3 may interact with calsenilin under one of these specific conditions. It is interesting that, in the developing mouse cerebellum, Notch expression was increased in the absence of CLN3 [168], and in *Drosophila*, overexpression of CLN3 caused the opposite effect: decreased Notch signaling and Notch-like phenotypes [170]. This is suggestive of a genetic interaction between CLN3 and the Notch signaling pathway.

Overexpression of CLN3 in the fly eye caused degeneration, and this phenotype was used to complete a genetic screen for genetic interactions [170]. This screen identified *mago nashi*, a constituent of the exon-exon-junction complex and a gene with roles in RNA transport and cell polarity in the developing oocyte of *Drosophila* [170–172] as an enhancer of the eye degeneration phenotype. Interestingly, it was recently reported that CLN3 interacts with the Shwachman-Bodian-Diamond Syndrome protein, SBDS [173]. *SBDS* is ubiquitously expressed and highly conserved [174], and due to the high conservation of this protein, studies to examine the function of Sdo1p, the yeast homolog of SBDS, have revealed further important information as to the function of this protein in RNA processing and ribosomal biogenesis [175, 176]. Specifically, Sdo1p is required for the release and recycling of ribosome maturation factor Tif6 from the pre-60S ribosomes in the cytoplasm [175]. SBDS is a multifunctional protein, involved in a complex interactome with proteins of the large ribosomal subunit (RPL4) and DNA metabolism (DNA-PK and RPA70), and cells depleted of SBDS exhibit increased sensitivity to DNA damage and ER stress [177]. The C-terminus of CLN3 was found by Cytotrap Y2H to interact with SBDS and this interaction was confirmed by co-immunoprecipitation of CLN3 and SBDS expressed in NIH-3T3 cells [173]. The CLN3–SBDS interaction is evolutionarily conserved since the *Saccharomyces cerevisiae* homologs to CLN3 (Btn1p) and SBDS (Sdo1p) interact [173]. Examination of this interaction indicated that during pH stress, Sdo1p may regulate Btn1p's functional modulation of the V-ATPase [173]. Shwachman-Diamond Syndrome is a disease characterized by exocrine pancreatic insufficiency, bone marrow deficiency, and skeletal dysplasia [178], which differs from JNCL pathology. However, some brain structural irregularities have been seen in SBDS patients [179]. CLN3 expression has been found in pancreatic islet cells [180], and both CLN3 and SBDS are expressed in adult mouse brain (Table 2). The interaction between Sdo1p and Btn1p functionally links lysosomal and ion homeostasis with the ribosome, possibly through a novel regulating mechanism.

The reported CLN3 genetic interaction with *mago nashi*, and the CLN3 physical interaction with SBDS, may potentially signify a conditionally regulated link in specific conditions. For example, SBDS was enriched in the pseudopod of *Dictostelium* amoebae migrating towards a chemoattractant [181], and likewise, the loss of SBDS in patient polymorphonuclear leukocytes prevented orientation and motility towards a chemoattractant [182]. CLN3 and SBDS may couple ribosome and localized translation to the pseudopod, where the chemoattractant signal is sensed and degraded in the lysosome. *Cln3*^{−/−} mouse embryonic fibroblasts exhibit cell motility defects, which could be due to the loss of an interaction of the C-terminus of CLN3 and nonmuscle myosin-IIb [220]. This interaction was found by Y2H and confirmed by co-immunoprecipitation of expressed CLN3 with endogenous myosin-IIb. An interaction of myosin-IIb with CLN3 has interesting implications for CLN3 function as it is an actin-binding motor protein with increased expression in the brain during

development, and is involved in cell motility, division, and polarity [183]. Calsenilin, SBDS, and myosin-IIb interact with the C-terminus of CLN3, indicating that this region of CLN3 may contain a novel binding motif or more likely exhibits labile or conditional interaction with each protein.

While the primary function of CLN3 remains elusive, it is apparent that CLN3 has multiple interaction partners with the potential to have an influence on many biological processes. However, the identification of interacting proteins is only a starting point for understanding the role of this protein in the CNS. The need for robust and verified antibodies that specifically bind CLN3 remains. Currently, immunoprecipitation of endogenous CLN3 is difficult, and experiments on the trafficking, localization, and function of CLN3 and CLN3 interactors present many challenges. Whether CLN3 interacts with these same proteins in all cell types, and in particular in all cell types of the CNS, at all points in development, remains unclear. It is possible that the regulation of these interactions occurs in both a temporal or spatial manner. Indeed, these interactions are not necessarily mutually exclusive. Moreover, many of the CLN3 interactors function at the cell periphery, and while CLN3 is likely primarily localized to the lysosome, CLN3 could have specific roles in vesicles at the cell periphery during certain conditions in integrating the response to alterations in localized ion homeostasis. The numerous interactions of CLN3 provide clues as to its function, though the primary functions are still unknown. Interactions have been described for CLN3 (Fig. 1b), implicating a functional role in cytoskeleton dynamics, ion channel trafficking, cell adhesion and migration, lysosomal/vacuolar homeostasis and modulation of ionic flux.

CLN6

Variant late infantile NCL (vLINCL) results from mutations in *CLN6* [184, 185]. CLN6 is found in the ER, and not in the Golgi or lysosomes [186–188]. CLN6 is a seven transmembrane domain protein with the N-terminus directed towards the cytoplasm and the C-terminus within the ER lumen (Fig. 1d) [188]. Through cross-linking experiments, CLN6 was shown to form homo-dimers which require both the N- and C-termini for dimerization [186, 188]. ER retention for CLN6 requires the N-terminus and transmembrane domains 6 and 7 [188]. Interestingly, similar cross-linking experiments did not reveal interactions between CLN6 and CLN8, both located in the ER membrane [188], indicating that these proteins do not form heterodimers and probably do not function together (Fig. 1d, Table 1).

CLN6^{−/−} cells from patients (vLINCL), mutant mice (*nclf*), or mutant sheep (*OCL6*^{−/−}) do not show defects in synthesis, sorting or processing of cathepsin D, which was used in this study as a prototypical lysosomal protein to reveal defects in lysosomal protein maturation in the loss of CLN6 in the ER [186]. However, in both *OCL6*^{−/−} and *CLN6*^{−/−} patient cells, endocytosis of arylsulfatase A (ASA) from the plasma membrane by the M6PR pathway was increased, and this effect was specific to the M6PR pathway since transferrin-mediated endocytosis was normal in these cells [186]. Interestingly, this defect was not in kinetics of endocytosis, but rather in degradation of ASA, as examined by pulse-chase autoradiography [186]. This experiment clearly shows that the ER-resident protein, CLN6,

is required for degradation pathways involving lysosomes, though the exact mechanism remains unclear.

Recently, peptide fragments of CLN6 were screened against a human fetal brain library using the CytoTrap Y2H, and CLN6 was shown to interact with collapsin response mediator protein-2 (CRMP-2), also known as dihydropyridine-iminase-like-2 (DRP-2) [189]. This interaction was validated by co-immunoprecipitation of overexpressed proteins in NIH-3T3 cells [189]. CRMP-2 is involved in neuronal polarity, growth cone guidance, and interacts with Numb at the growth cone of neurons to mediate endocytosis of L1 [190–193]. CRMP-2 binds tubulin heterodimers and the Sra-1/WAVE1-actin complex and so mediates axon dynamics and specification [194, 195]. Therefore, an interaction of CLN6 with CRMP-2 may have implications in the CNS of vLINCL patients. CRMP-2 is involved in semaphorin signaling pathways to guide axonal growth cones, but no alterations in semaphorin-3A signaling were observed in *ncl* dorsal root ganglion explants [189]. However, there was a defect in the maturation of hippocampal neurons in a co-culture system of glia and hippocampal neurons from *ncl* mice [189]. Alterations in CRMP-2 protein expression levels were also seen in specific brain regions of the *ncl* mouse [189]. CRMP-2 and CLN6 are both well expressed in the developing mouse brain (Table 2). Thus, the interaction of CLN6 with CRMP-2 may have implications in the maturation and integrity of axonal outgrowth in vLINCL patients, though the exact function of this interaction or of CLN6 remains unknown.

CLN7/MFSD8

Variant late infantile NCL, resulting from mutations in *CLN7*, was originally termed the Turkish variant [196, 197], but was later found in broader populations [198, 199]. The CLN7 protein is predicted to be a 518 amino acid protein, approximately 58 kDa, with 12 predicted transmembrane domains and both the N- and C-terminus facing the cytosol (Fig. 1e, Table 1) [200, 201]. Recently, the protein was identified as a member of the major facilitator superfamily (MFS), by amino acid sequence homology; therefore, the gene locus was identified to be MFS-domain containing protein-8 (MFSD8) [200]. MFS domain proteins are ubiquitously expressed, conserved, and function as transporters of small solutes by chemiosmotic gradients [202], though the substrate specificity of CLN7/MFSD8 has not been determined [200]. Overexpressed GFP-tagged CLN7/MFSD8 was localized to the lysosomes in COS-1 cells and HeLa cells (Fig. 1e), and CLN7/MFSD8 is thought to act as a novel lysosomal transporter [200, 201]. CLN7/MFSD8 is glycosylated at two positions (N371, N376), which are not required for lysosomal targeting of CLN7/MFSD8 [201]. Two dileucine-based sorting motifs, N-terminal [D/E]XXXL[L/I]-type (E⁹QEPL¹³L¹⁴) and two YXXØ-type tyrosine-based motifs (Y⁵⁰³KRL and Y⁵¹³GRI) in the C-terminus both contribute to targeting the protein to the plasma membrane and clathrin-mediated endocytosis; however, the dileucine motif is the dominant signal for lysosomal targeting from the cell surface [201]. The interactions and primary functions of CLN7/MFSD8 have not been elucidated.

CLN8

CLN8 mutations result in progressive epilepsy with mental retardation (EPMR, also known as Northern Epilepsy), or variant late-infantile NCL progression [203–207]. *CLN8* mutations spontaneously occurring in mice resulted in the motor neuron degeneration phenotype (*mnd*) [204, 208]. The brains of *mnd* mice and NCL patients show accumulation of autofluorescent storage material and neurodegeneration. The CLN8 protein is a membrane protein of 286 amino acids and approximately 33 kDa that localizes to the endoplasmic reticulum (ER) and the ER to Golgi intermediate compartment (ERGIC), in BHK cells (Fig. 1d, Table 1) [209]. CLN8 contains an ER-retrieval signal (KKRP) that directs retention of the protein; patient mutations did not affect this ER localization [209]. CLN8 is not proteolytically processed or glycosylated [209]. In neuronal cells, transfected primary hippocampal neurons, CLN8 was found to colocalize with ER markers, but CLN8 staining extended beyond the ER markers towards the periphery of the neurons [210]. Similarly in polarized epithelial CaCo-2 cells, CLN8 staining was found beyond the ER and ERGIC compartment and extended to the basolateral surface of these cells [210]. Further, CLN8 from mouse brain extracts fractionated separately from ER and ERGIC, as well as synaptic markers, indicating that CLN8 may have a unique, unidentified vesicular localization in neurons [210]. It is possible that artifacts of CLN8 staining exist due to overexpression in these studies.

PSI-BLAST analysis identified CLN8 sequence similarity with yeast Lag1p, a protein involved in longevity and aging [211] and TRAM, a regulator of translocation into the ER [212], and through these similarities, functions for CLN8 were suggested in lipid synthesis, proteolipid trafficking, or lipid sensing [213], though these suggestions have not been tested directly. Interestingly, examination of brain samples from two EPMR patients by liquid chromatography/mass spectrometry revealed reduced levels of ceramide, galactosylceramide, lactosylceramide, and sulfatide accompanied with increases in polyunsaturated acyl chain species such as phosphatidylserines and phosphatidylethanolamines [214]. There were no changes in total phospholipid content, but these alterations in the composition of phospholipid and sphingolipid species may increase lipid oxidation or affect specific membrane dynamics and function of membrane receptors, contributing to the pathology of EPMR [214]. Similarly, *mnd* mice also have disturbances in lipid metabolism proteins in the liver [215], and taken together these studies support a role for CLN8 in lipid homeostasis, though the direct function of CLN8 protein in these pathways remains unclear. Interacting partners of CLN8 in the ER, ERGIC, and beyond these compartments in neurons have not been reported, but identification of interactions may offer valuable insight into the function of CLN8 in lipid homeostasis, or how the loss of CLN8 precipitates these changes.

Do NCL proteins interact and participate in a common pathway?

Deficiency in eight separate genes results in the accumulation of autofluorescent storage material. Thus, it is tempting to hypothesize that there is a functional link between the NCL proteins or that they interact directly in one pathway. This hypothesis was examined by classic Y2H of the NCL proteins, which showed that none interacted [216]; however, subsequent studies reexamined these potential interactions.

Initially, PPT1 was not found to interact with any other NCL proteins by co-immunoprecipitation (co-IP) of over-expressed proteins in COS-1 cells; however TPP1 and CLN3 were found to interact with CLN5 [95]. In this study, antibodies to PPT1, TPP1, CLN3, and CLN5 were all generated in rabbit and used for immunoprecipitation (IP) of overexpressed proteins from COS-1 cell extracts. To identify an interaction, an IP was performed with a rabbit-generated antibody and to detect the co-IP protein, the second protein was immunoblotted, using a second rabbit antibody [95]. Thus, unless unreported actions were taken to prevent antibody cross-reactivity, for instance cross-linking the IP antibody to protein-A agarose beads, the bands in these co-IP immunoblots may simply be IgG bands. This does not explain why PPT1 did not appear to IP, but it may explain why LAMP1 did not co-IP in the negative control, because the LAMP1 antibody (H4A3) is a mouse monoclonal [95], which would not result in the same IgG cross-reactivity. No sizes were reported on the immunoblot to indicate if the bands were in fact IgG or specific to the NCL protein, so the validity of this experiment is unclear [95]. Antibodies to most of the NCL proteins are of questionable specificity and avidity; for example, several reports indicate that antibodies to CLN5 do not recognize endogenously expressed CLN5, and study of CLN5 requires overexpression for both immunoblotting and immunocytochemistry [95, 98, 102]. Therefore, over-expressed and epitope-tagged proteins are used to identify localization and interactions, which is acceptable when the appropriate controls are used. Unfortunately, vector-only transfection controls are not presented in several localization studies of CLN5 [95, 98, 102], and not used in all immunoblotting experiments. Moreover, the specificity of the NCL antibodies used in most studies are usually not validated, verified, or reported.

Recently, CLN5 was again reported to interact with PPT1, TPP1, CLN3, CLN6 and CLN8 in vitro [95, 105]. GST-CLN5 expressed in *E. coli* and was used for in vitro binding assays to show interactions of CLN5 with the other NCL proteins [105]. GST-CLN5 was reported to interact with overexpressed PPT1, CLN3, CLN6-myc, and CLN8-HA in COS-1 cell extracts, but not with endogenously expressed LAMP1 [105]. It was also reported that GST-CLN5 interacted with the α and β subunits of the F_1 -complex of the ATP synthase [105]. GST-CLN5 was also shown to interact with endogenous TPP1 [105]. Overall, the fact that the CLN5 used in these studies was fused with GST raises some questions about these interactions. While it was appropriately demonstrated that the GST alone did not interact with other NCL-proteins, CLN5 was ultimately isolated from *E. coli*. Expressing a highly modified protein like CLN5 in *E. coli* probably does not necessarily produce a native CLN5 protein; and native structure is required for a binding assay to identify relevant protein interactions. CLN5 would not be glycosylated properly in *E. coli*, the N-terminal signal sequence would probably not be cleaved, and the protein may even be incapable of folding correctly without ER-processing [95, 98, 99, 102, 105]. Further, the purity of the GST-CLN5 yielded from the glutathione-Sepharose purification, and used for affinity-precipitation experiments, was not shown; therefore, the interactions that were reported in [105] could be the result of many nonspecific interactions occurring with other contaminating proteins, or could be due to aggregation of the hydrophobic NCL proteins themselves.

In terms of the specific interactions shown in this study [105], PPT1 and CLN3, tagged CLN6 and tagged CLN8, were all overexpressed in COS-1 cells. Overexpression of these proteins may affect their structure or interactions, as certain NCL proteins can dimerize (for example, CLN6 [188]), and produce interactions in cell extracts that would not occur in the cell. Interactions with CLN6 and CLN8 would have to occur while CLN5 is present in the ER, and CLN3, PPT1, and TPP1 would interact with CLN5 at the lysosome; however, each of these interactions are possible in a cell extract where spatial constraints of the cell are lost. The effect of overexpression of a trafficking-deficient CLN5 (CLN5-TD) on the localization of the NCL proteins was examined, and showed that co-overexpressed PPT1 was also retained in the ER with CLN5-TD [105]. This is not surprising, as overexpression of proteins could result in ER retention, therefore any link between these proteins due to the common retention in the ER under overexpression conditions probably is not relevant to their function.

TPP1, CLN3, CLN6, and CLN8 were also reported to interact by co-immunoprecipitation and co-localization from lymphoblast and fibroblast cell lines derived from NCL patients or NCL mutant mice [217]. Unfortunately, this study is wrought with technical concerns such as a co-localization by immunocytochemistry that used improper pairing of secondary antibody species and resulted in false-positive co-localization [217]. A sheep anti-CLN6 antibody and a sheep anti-CLN8 antibody were used to co-localize CLN6 and CLN8 in human fibroblasts, which will result with anti-Sheep IgG cross-reactivity. Immunoprecipitation of CLN3 and CLN2 from lymphoblasts using rabbit anti-CLN3 and rabbit anti-CLN2 antibodies was followed by immunoblotting with the same rabbit antibodies for detecting co-immunoprecipitation, again causing anti-rabbit-IgG-HRP cross-reactivity [217]. Curiously, the immunoprecipitation immunoblots are in fact showing bands that are most likely the IgG from the antibodies used for the immunoprecipitation, rather than the NCL proteins. Additionally, the primary antibodies used were of dubious specificity to NCL proteins, as no validation of the antibodies was published with the study. CLN5 was not addressed in this work, and therefore any comparison between it and the work of Lyly et al. [105] is not appropriate.

When considering the interactions of the NCL proteins, it is important to consider the tissue and developmental expression of these genes and therefore the likelihood of an in vitro interaction having biological significance. The genes encoding NCL proteins are differentially expressed in the mouse brain in both a spatial and temporal manner, according to in situ images of the St. Jude Brain Gene Expression Map (Table 2) (<http://www.stjudebgem.org/>, 2010). For example, at embryonic day 15, TPP1 is well expressed in the ventricles of the developing mouse brain, a location and time point where there is little expression of CLN3, CLN5, CLN6, or CLN8, but high expression of cathepsin D. Indeed, CLN5 and CLN8 expression throughout mouse brain development are both quite low compared to other NCL proteins, and they do not correlate with expression of any of the other NCL proteins in this database. This database provides information only on the transcript expression of these proteins, and it is also possible that expression exists at sub-detectable levels, or at later stages of development since the oldest age examined was postnatal day 42.

Because mutations in many different NCL proteins result in common disease, it is tempting to simplify the mechanism of pathology to a common pathway; however, it is likely that NCL is much more complicated. Not surprisingly, comparison of mouse models for different NCLs show similar disruptions, for example in *Cln1*^{-/-} and *Cln5*^{-/-} mice have similar alterations in brain gene expression profiles [218]. It is probable that NCL proteins are multi-functional cell players that interact with different proteins in various locations in the cell, and perhaps even in diverse types of cells in a temporally regulated manner. Inevitably, the context of a neuron must be considered for NCL protein function, as these are the cells that are most sensitive to the loss of these proteins. It is not clear if neurons are more sensitive to storage material accumulation, or to the processes that are disrupted to cause the accumulation of storage material. Experiments to transfer storage material to wild type cells could answer this question. It is likely the answer is a combination of the two. The localizations of NCL proteins indicate that NCL is a cellular disorder of different pathways converging on the same disease. Neurons are highly specialized, highly polarized, and post-mitotic cells that exist in a state of constant ionic flux and rely heavily on the secretory system for neurotransmission. PPT1 has been found down axons and in synaptic vesicles [56] and CLN3 has been found in synaptosomes [120], providing evidence that NCL proteins can be found in the processes of neurons beyond just the lysosome in the cell soma. These localizations could indicate specific roles for the NCL proteins in neurons that are not yet well understood.

Concluding remarks

Neuronal Ceroid Lipofuscinosis is a lysosomal storage disorder that is caused by mutations in eight different proteins that reside in the lysosome, ER, and other regions of the cell. The dysfunction caused by the loss of functional NCL proteins results in neurodegeneration and central nervous system pathology. Though we know the NCLs to be neurodegenerative diseases, the mechanism of the pathology has not been clearly defined; whether loss of neurons is precipitated by accumulation of toxic storage material in neurons, or by the loss of the functional proteins directly, is still a topic of debate. Additionally, the importance of NCL proteins in the support cells of the brain and other tissues has not been assessed. It is unlikely that interactions between the NCL proteins have biological significance; however, understanding the interactome of each of the NCL proteins with their substrates or binding partners will offer insight into the pathways affected in NCL, and how these pathways converge in lysosomal dysfunction.

Acknowledgments

The authors wish to acknowledge their sources of funding: National Institutes of Health (NIH) Institutional Ruth L. Kirschstein National Research Service Award [GM068411] (A.L.G), NIH R01 NS36610, NIH R01 NS43310 and the Batten Disease Support and Research Association.

References

1. Futerman AH, van Meer G. The cell biology of lysosomal storage disorders. *Nat Rev Mol Cell Biol.* 2004; 5:554–565. [PubMed: 15232573]
2. Goebel, HH.; Mole, S.; Lake, BD. The neuronal ceroid lipofuscinoses (Batten Disease). IOS Press; Amsterdam, Netherlands: 1999.

3. Mole SE, Williams RE, Goebel HH. Correlations between genotype, ultrastructural morphology and clinical phenotype in the neuronal ceroid lipofuscinoses. *Neurogenetics*. 2005; 6:107–126. [PubMed: 15965709]
4. Cooper JD, Russell C, Mitchison HM. Progress towards understanding disease mechanisms in small vertebrate models of neuronal ceroid lipofuscinosis. *Biochim Biophys Acta*. 2006; 1762:873–889. [PubMed: 17023146]
5. Lu JY, Hu J, Hofmann SL. Human recombinant palmitoyl-protein thioesterase-1 (PPT1) for preclinical evaluation of enzyme replacement therapy for infantile neuronal ceroid lipofuscinosis. *Mol Genet Metab*. 2010; 99:374–378. [PubMed: 20036592]
6. Chang M, Cooper JD, Sleat DE, Cheng SH, Dodge JC, Passini MA, Lobel P, Davidson BL. Intraventricular enzyme replacement improves disease phenotypes in a mouse model of late infantile neuronal ceroid lipofuscinosis. *Mol Ther*. 2008; 16:649–656. [PubMed: 18362923]
7. Griffey MA, Wozniak D, Wong M, Bible E, Johnson K, Rothman SM, Wentz AE, Cooper JD, Sands MS. CNS-directed AAV2-mediated gene therapy ameliorates functional deficits in a murine model of infantile neuronal ceroid lipofuscinosis. *Mol Ther*. 2006; 13:538–547. [PubMed: 16364693]
8. Passini MA, Dodge JC, Bu J, Yang W, Zhao Q, Sondhi D, Hackett NR, Kaminsky SM, Mao Q, Shihabuddin LS, Cheng SH, Sleat DE, Stewart GR, Davidson BL, Lobel P, Crystal RG. Intracranial delivery of CLN2 reduces brain pathology in a mouse model of classical late infantile neuronal ceroid lipofuscinosis. *J Neurosci*. 2006; 26:1334–1342. [PubMed: 16452657]
9. Tamaki SJ, Jacobs Y, Dohse M, Capela A, Cooper JD, Reitsma M, He D, Tushinski R, Belichenko PV, Salehi A, Mobley W, Gage FH, Huhn S, Tsukamoto AS, Weissman IL, Uchida N. Neuroprotection of host cells by human central nervous system stem cells in a mouse model of infantile neuronal ceroid lipofuscinosis. *Cell Stem Cell*. 2009; 5:310–319. [PubMed: 19733542]
10. Palmer DN, Jolly RD, van Mil HC, Tynnela J, Westlake VJ. Different patterns of hydrophobic protein storage in different forms of neuronal ceroid lipofuscinosis (NCL, Batten disease). *Neuropediatrics*. 1997; 28:45–48. [PubMed: 9151321]
11. Palmer DN, Fearnley IM, Walker JE, Hall NA, Lake BD, Wolfe LS, Haltia M, Martinus RD, Jolly RD. Mitochondrial ATP synthase subunit c storage in the ceroid-lipofuscinoses (Batten disease). *Am J Med Genet*. 1992; 42:561–567. [PubMed: 1535179]
12. Seehafer SS, Pearce DA. You say lipofuscin, we say ceroid: defining autofluorescent storage material. *Neurobiol Aging*. 2006; 27:576–588. [PubMed: 16455164]
13. Siintola E, Partanen S, Stromme P, Haapanen A, Haltia M, Maehlen J, Lehesjoki AE, Tynnela J. Cathepsin D deficiency underlies congenital human neuronal ceroid-lipofuscinosis. *Brain*. 2006; 129:1438–1445. [PubMed: 16670177]
14. Phillips SN, Muzaffar N, Codlin S, Korey CA, Taschner PE, de Voer G, Mole SE, Pearce DA. Characterizing pathogenic processes in Batten disease: use of small eukaryotic model systems. *Biochim Biophys Acta*. 2006; 1762:906–919. [PubMed: 17049819]
15. Zaidi N, Maurer A, Nieke S, Kalbacher H. Cathepsin D: a cellular roadmap. *Biochem Biophys Res Commun*. 2008; 376:5–9. [PubMed: 18762174]
16. Benes P, Vetvicka V, Fusek M. Cathepsin D—many functions of one aspartic protease. *Crit Rev Oncol Hematol*. 2008; 68:12–28. [PubMed: 18396408]
17. Ramirez-Montealegre D, Rothberg PG, Pearce DA. Another disorder finds its gene. *Brain*. 2006; 129:1353–1356. [PubMed: 16738059]
18. Steinfeld R, Reinhardt K, Schreiber K, Hillebrand M, Kraetzner R, Bruck W, Saftig P, Gartner J. Cathepsin D deficiency is associated with a human neurodegenerative disorder. *Am J Hum Genet*. 2006; 78:988–998. [PubMed: 16685649]
19. Awano T, Katz ML, O'Brien DP, Taylor JF, Evans J, Khan S, Sohar I, Lobel P, Johnson GS. A mutation in the cathepsin D gene (CTSD) in American Bulldogs with neuronal ceroid lipofuscinosis. *Mol Genet Metab*. 2006; 87:341–348. [PubMed: 16386934]
20. Myllykangas L, Tynnela J, Page-McCaw A, Rubin GM, Haltia MJ, Feany MB. Cathepsin D-deficient *Drosophila* recapitulate the key features of neuronal ceroid lipofuscinoses. *Neurobiol Dis*. 2005; 19:194–199. [PubMed: 15837574]

21. Tyynela J, Sohar I, Sleat DE, Gin RM, Donnelly RJ, Baumann M, Haltia M, Lobel P. A mutation in the ovine cathepsin D gene causes a congenital lysosomal storage disease with profound neurodegeneration. *EMBO J.* 2000; 19:2786–2792. [PubMed: 10856224]
22. Koike M, Shibata M, Ohsawa Y, Nakanishi H, Koga T, Kametaka S, Waguri S, Momoi T, Kominami E, Peters C, Figura K, Saftig P, Uchiyama Y. Involvement of two different cell death pathways in retinal atrophy of cathepsin D-deficient mice. *Mol Cell Neurosci.* 2003; 22:146–161. [PubMed: 12676526]
23. Koike M, Nakanishi H, Saftig P, Ezaki J, Isahara K, Ohsawa Y, Schulz-Schaeffer W, Watanabe T, Waguri S, Kametaka S, Shibata M, Yamamoto K, Kominami E, Peters C, von Figura K, Uchiyama Y. Cathepsin D deficiency induces lysosomal storage with ceroid lipofuscin in mouse CNS neurons. *J Neurosci.* 2000; 20:6898–6906. [PubMed: 10995834]
24. Shevtsova Z, Garrido M, Weishaupt J, Saftig P, Bahr M, Luhder F, Kugler S. CNS-Expressed Cathepsin D Prevents Lymphopenia in a Murine Model of Congenital Neuronal Ceroid Lipofuscinosis. *Am J Pathol.* 2010;10.2353/ajpath.2010.091267[25]
25. Masson O, Bach AS, Derocq D, Prebois C, Laurent-Matha V, Pattingre S, Liaudet-Coopman E. Pathophysiological functions of cathepsin D: targeting its catalytic activity versus its protein binding activity? *Biochimie.* 2010;10.1016/j.biochi.2010.05.009
26. Kenessey A, Nacharaju P, Ko LW, Yen SH. Degradation of tau by lysosomal enzyme cathepsin D: implication for Alzheimer neurofibrillary degeneration. *J Neurochem.* 1997; 69:2026–2038. [PubMed: 9349548]
27. Heinrich M, Neumeyer J, Jakob M, Hallas C, Tchikov V, Winoto-Morbach S, Wickel M, Schneider-Brachert W, Trauzold A, Hethke A, Schutze S. Cathepsin D links TNF-induced acid sphingomyelinase to Bid-mediated caspase-9 and -3 activation. *Cell Death Differ.* 2004; 11:550–563. [PubMed: 14739942]
28. Saftig P, Hetman M, Schmahl W, Weber K, Heine L, Mossmann H, Koster A, Hess B, Evers M, von Figura K, Peters C. Mice deficient for the lysosomal proteinase cathepsin D exhibit progressive atrophy of the intestinal mucosa and profound destruction of lymphoid cells. *EMBO J.* 1995; 14:3599–3608. [PubMed: 7641679]
29. Sagulenko V, Muth D, Sagulenko E, Paffhausen T, Schwab M, Westermann F. Cathepsin D protects human neuroblastoma cells from doxorubicin-induced cell death. *Carcinogenesis.* 2008; 29:1869–1877. [PubMed: 18566016]
30. Johansson AC, Steen H, Ollinger K, Roberg K. Cathepsin D mediates cytochrome c release and caspase activation in human fibroblast apoptosis induced by staurosporine. *Cell Death Differ.* 2003; 10:1253–1259. [PubMed: 14576777]
31. Schestkova O, Geisel D, Jacob R, Hasilik A. The catalytically inactive precursor of cathepsin D induces apoptosis in human fibroblasts and HeLa cells. *J Cell Biochem.* 2007; 101:1558–1566. [PubMed: 17340625]
32. Tyynela J, Sohar I, Sleat DE, Gin RM, Donnelly RJ, Baumann M, Haltia M, Lobel P. Congenital ovine neuronal ceroid lipofuscinosis—a cathepsin D deficiency with increased levels of the inactive enzyme. *Eur J Paediatr Neurol.* 2001; 5(Suppl A):43–45. [PubMed: 11589006]
33. Walls KC, Klocke BJ, Saftig P, Shibata M, Uchiyama Y, Roth KA, Shacka JJ. Altered regulation of phosphatidylinositol 3-kinase signaling in cathepsin D-deficient brain. *Autophagy.* 2007; 3:222–229. [PubMed: 17297299]
34. Haidar B, Kiss RS, Sarov-Blat L, Brunet R, Harder C, McPherson R, Marcel YL. Cathepsin D, a lysosomal protease, regulates ABCA1-mediated lipid efflux. *J Biol Chem.* 2006; 281:39971–39981. [PubMed: 17032648]
35. Wang MD, Franklin V, Sundaram M, Kiss RS, Ho K, Gallant M, Marcel YL. Differential regulation of ATP binding cassette protein A1 expression and ApoA-I lipidation by Niemann-Pick type C1 in murine hepatocytes and macrophages. *J Biol Chem.* 2007; 282:22525–22533. [PubMed: 17553802]
36. Jabs S, Quitsch A, Kakela R, Koch B, Tyynela J, Brade H, Glatzel M, Walkley S, Saftig P, Vanier MT, Braulke T. Accumulation of bis(monoacylglycero)phosphate and gangliosides in mouse models of neuronal ceroid lipofuscinosis. *J Neurochem.* 2008; 106:1415–1425. [PubMed: 18498441]

37. Mutka AL, Haapanen A, Kakela R, Lindfors M, Wright AK, Inkinen T, Hermansson M, Rokka A, Corthals G, Jauhiainen M, Gillingwater TH, Ikonen E, Tyynela J. Murine cathepsin D deficiency is associated with dysmyelination/myelin disruption and accumulation of cholesteryl esters in the brain. *J Neurochem.* 2010; 112:193–203. [PubMed: 19845830]
38. el-Husseini Ael D, Brecht DS. Protein palmitoylation: a regulator of neuronal development and function. *Nat Rev Neurosci.* 2002; 3:791–802. [PubMed: 12360323]
39. Mitchison HM, Hofmann SL, Becerra CH, Munroe PB, Lake BD, Crow YJ, Stephenson JB, Williams RE, Hofman IL, Taschner PE, Martin JJ, Philippart M, Andermann E, Andermann F, Mole SE, Gardiner RM, O'Rawe AM. Mutations in the palmitoyl-protein thioesterase gene (PPT; CLN1) causing juvenile neuronal ceroid lipofuscinosis with granular osmio-philic deposits. *Hum Mol Genet.* 1998; 7:291–297. [PubMed: 9425237]
40. Hofmann SL, Das AK, Yi W, Lu JY, Wisniewski KE. Genotype-phenotype correlations in neuronal ceroid lipofuscinosis due to palmitoyl-protein thioesterase deficiency. *Mol Genet Metab.* 1999; 66:234–239. [PubMed: 10191107]
41. Vesa J, Hellsten E, Verkruyse LA, Camp LA, Rapola J, Santavuori P, Hofmann SL, Peltonen L. Mutations in the palmitoyl protein thioesterase gene causing infantile neuronal ceroid lipofuscinosis. *Nature.* 1995; 376:584–587. [PubMed: 7637805]
42. Camp LA, Verkruyse LA, Afendis SJ, Slaughter CA, Hofmann SL. Molecular cloning and expression of palmitoyl-protein thioesterase. *J Biol Chem.* 1994; 269:23212–23219. [PubMed: 7916016]
43. Sleat DE, Sohar I, Lackland H, Majercak J, Lobel P. Rat brain contains high levels of mannose-6-phosphorylated glyco-proteins including lysosomal enzymes and palmitoyl-protein thioesterase, an enzyme implicated in infantile neuronal lipofuscinosis. *J Biol Chem.* 1996; 271:19191–19198. [PubMed: 8702598]
44. Hofmann SL, Atashband A, Cho SK, Das AK, Gupta P, Lu JY. Neuronal ceroid lipofuscinoses caused by defects in soluble lysosomal enzymes (CLN1 and CLN2). *Curr Mol Med.* 2002; 2:423–437. [PubMed: 12125808]
45. Das AK, Lu JY, Hofmann SL. Biochemical analysis of mutations in palmitoyl-protein thioesterase causing infantile and late-onset forms of neuronal ceroid lipofuscinosis. *Hum Mol Genet.* 2001; 10:1431–1439. [PubMed: 11440996]
46. Mazzei R, Conforti FL, Magariello A, Bravaccio C, Militeri R, Gabriele AL, Sampaolo S, Patitucci A, Di Iorio G, Muglia M, Quattrone A. A novel mutation in the CLN1 gene in a patient with juvenile neuronal ceroid lipofuscinosis. *J Neurol.* 2002; 249:1398–1400. [PubMed: 12382155]
47. Kalviainen R, Eriksson K, Losekoot M, Sorri I, Harvima I, Santavuori P, Jarvela I, Autti T, Vanninen R, Salmenpera T, van Diggelen OP. Juvenile-onset neuronal ceroid lipofuscinosis with infantile CLN1 mutation and palmitoyl-protein thioesterase deficiency. *Eur J Neurol.* 2007; 14:369–372. [PubMed: 17388982]
48. Griffey M, Bible E, Vogler C, Levy B, Gupta P, Cooper J, Sands MS. Adeno-associated virus 2-mediated gene therapy decreases autofluorescent storage material and increases brain mass in a murine model of infantile neuronal ceroid lipofuscinosis. *Neurobiol Dis.* 2004; 16:360–369. [PubMed: 15193292]
49. Griffey M, Macauley SL, Ogilvie JM, Sands MS. AAV2-mediated ocular gene therapy for infantile neuronal ceroid lipofuscinosis. *Mol Ther.* 2005; 12:413–421. [PubMed: 15979943]
50. Bellizzi JJ 3rd, Widom J, Kemp C, Lu JY, Das AK, Hofmann SL, Clardy J. The crystal structure of palmitoyl protein thioesterase 1 and the molecular basis of infantile neuronal ceroid lipofuscinosis. *Proc Natl Acad Sci USA.* 2000; 97:4573–4578. [PubMed: 10781062]
51. Hellsten E, Vesa J, Olkkonen VM, Jalanko A, Peltonen L. Human palmitoyl protein thioesterase: evidence for lysosomal targeting of the enzyme and disturbed cellular routing in infantile neuronal ceroid lipofuscinosis. *EMBO J.* 1996; 15:5240–5245. [PubMed: 8895569]
52. Lyly A, von Schantz C, Salonen T, Kopra O, Saarela J, Jauhiainen M, Kytälä A, Jalanko A. Glycosylation, transport, and complex formation of palmitoyl protein thioesterase 1 (PPT1)—distinct characteristics in neurons. *BMC Cell Biol.* 2007; 8:22. [PubMed: 17565660]

53. Verkruyse LA, Hofmann SL. Lysosomal targeting of palmitoyl-protein thioesterase. *J Biol Chem.* 1996; 271:15831–15836. [PubMed: 8663305]
54. Lu JY, Verkruyse LA, Hofmann SL. The effects of lysosomotropic agents on normal and INCL cells provide further evidence for the lysosomal nature of palmitoyl-protein thioesterase function. *Biochim Biophys Acta.* 2002; 1583:35–44. [PubMed: 12069847]
55. Camp LA, Hofmann SL. Purification and properties of a palmitoyl-protein thioesterase that cleaves palmitate from H-Ras. *J Biol Chem.* 1993; 268:22566–22574. [PubMed: 7901201]
56. Ahtiainen L, Van Diggelen OP, Jalanko A, Kopra O. Palmitoyl protein thioesterase 1 is targeted to the axons in neurons. *J Comp Neurol.* 2003; 455:368–377. [PubMed: 12483688]
57. Heinonen O, Kytälä A, Lehmus E, Paunio T, Peltonen L, Jalanko A. Expression of palmitoyl protein thioesterase in neurons. *Mol Genet Metab.* 2000; 69:123–129. [PubMed: 10720439]
58. Lehtovirta M, Kytälä A, Eskelinen EL, Hess M, Heinonen O, Jalanko A. Palmitoyl protein thioesterase (PPT) localizes into synaptosomes and synaptic vesicles in neurons: implications for infantile neuronal ceroid lipofuscinosis (INCL). *Hum Mol Genet.* 2001; 10:69–75. [PubMed: 11136716]
59. Kim SJ, Zhang Z, Sarkar C, Tsai PC, Lee YC, Dye L, Mukherjee AB. Palmitoyl protein thioesterase-1 deficiency impairs synaptic vesicle recycling at nerve terminals, contributing to neuropathology in humans and mice. *J Clin Invest.* 2008; 118:3075–3086. [PubMed: 18704195]
60. Virmani T, Gupta P, Liu X, Kavalali ET, Hofmann SL. Progressively reduced synaptic vesicle pool size in cultured neurons derived from neuronal ceroid lipofuscinosis-1 knockout mice. *Neurobiol Dis.* 2005; 20:314–323. [PubMed: 16242638]
61. Tynnelä J, Palmer DN, Baumann M, Haltia M. Storage of saposins A and D in infantile neuronal ceroid-lipofuscinosis. *FEBS Lett.* 1993; 330:8–12. [PubMed: 8370464]
62. Kim SJ, Zhang Z, Lee YC, Mukherjee AB. Palmitoyl-protein thioesterase-1 deficiency leads to the activation of caspase-9 and contributes to rapid neurodegeneration in INCL. *Hum Mol Genet.* 2006; 15:1580–1586. [PubMed: 16571600]
63. Kim SJ, Zhang Z, Hitomi E, Lee YC, Mukherjee AB. Endoplasmic reticulum stress-induced caspase-4 activation mediates apoptosis and neurodegeneration in INCL. *Hum Mol Genet.* 2006; 15:1826–1834. [PubMed: 16644870]
64. Wei H, Kim SJ, Zhang Z, Tsai PC, Wisniewski KE, Mukherjee AB. ER and oxidative stresses are common mediators of apoptosis in both neurodegenerative and non-neurodegenerative lysosomal storage disorders and are alleviated by chemical chaperones. *Hum Mol Genet.* 2008; 17:469–477. [PubMed: 17989065]
65. Zhang Z, Lee YC, Kim SJ, Choi MS, Tsai PC, Xu Y, Xiao YJ, Zhang P, Heffer A, Mukherjee AB. Palmitoyl-protein thioesterase-1 deficiency mediates the activation of the unfolded protein response and neuronal apoptosis in INCL. *Hum Mol Genet.* 2006; 15:337–346. [PubMed: 16368712]
66. Tardy C, Sabourdy F, Garcia V, Jalanko A, Therville N, Levade T, Andrieu-Abadie N. Palmitoyl protein thioesterase 1 modulates tumor necrosis factor alpha-induced apoptosis. *Biochim Biophys Acta.* 2009; 1793:1250–1258. [PubMed: 19345705]
67. Macauley SL, Wozniak DF, Kielar C, Tan Y, Cooper JD, Sands MS. Cerebellar pathology and motor deficits in the palmitoyl protein thioesterase 1-deficient mouse. *Exp Neurol.* 2009; 217:124–135. [PubMed: 19416667]
68. Ahtiainen L, Kolikova J, Mutka AL, Luiro K, Gentile M, Ikonen E, Khiroug L, Jalanko A, Kopra O. Palmitoyl protein thioesterase 1 (Ppt1)-deficient mouse neurons show alterations in cholesterol metabolism and calcium homeostasis prior to synaptic dysfunction. *Neurobiol Dis.* 2007; 28:52–64. [PubMed: 17656100]
69. Buff H, Smith AC, Korey CA. Genetic modifiers of *Drosophila* palmitoyl-protein thioesterase 1-induced degeneration. *Genetics.* 2007; 176:209–220. [PubMed: 17409080]
70. Korey CA, MacDonald ME. An over-expression system for characterizing Ppt1 function in *Drosophila*. *BMC Neurosci.* 2003; 4:30. [PubMed: 14629778]
71. Lyly A, Marjavaara SK, Kytälä A, Uusi-Rauva K, Luiro K, Kopra O, Martinez LO, Tanhuanpää K, Kalkkinen N, Suomalainen A, Jauhainen M, Jalanko A. Deficiency of the INCL protein Ppt1

- results in changes in ectopic F1-ATP synthase and altered cholesterol metabolism. *Hum Mol Genet.* 2008; 17:1406–1417. [PubMed: 18245779]
72. Cottone CD, Chattopadhyay S, Pearce DA. Searching for interacting partners of CLN1, CLN2 and Btn1p with the two-hybrid system. *Eur J Paediatr Neurol.* 2001; 5(Suppl A):95–98. [PubMed: 11589016]
73. Wisniewski KE, Kida E, Walus M, Wujek P, Kaczmarek W, Golabek AA. Tripeptidyl-peptidase I in neuronal ceroid lipofuscinoses and other lysosomal storage disorders. *Eur J Paediatr Neurol.* 2001; 5(Suppl A):73–79. [PubMed: 11589013]
74. Sleat DE, Donnelly RJ, Lackland H, Liu CG, Sohar I, Pullarkat RK, Lobel P. Association of mutations in a lysosomal protein with classical late-infantile neuronal ceroid lipofuscinosis. *Science.* 1997; 277:1802–1805. [PubMed: 9295267]
75. Sleat DE, Gin RM, Sohar I, Wisniewski K, Sklower-Brooks S, Pullarkat RK, Palmer DN, Lerner TJ, Boustany RM, Uldall P, Siakotos AN, Donnelly RJ, Lobel P. Mutational analysis of the defective protease in classic late-infantile neuronal ceroid lipofuscinosis, a neurodegenerative lysosomal storage disorder. *Am J Hum Genet.* 1999; 64:1511–1523. [PubMed: 10330339]
76. Golabek AA, Kida E. Tripeptidyl-peptidase I in health and disease. *Biol Chem.* 2006; 387:1091–1099. [PubMed: 16895480]
77. Ezaki J, Takeda-Ezaki M, Oda K, Kominami E. Characterization of endopeptidase activity of tripeptidyl peptidase-I/CLN2 protein which is deficient in classical late infantile neuronal ceroid lipofuscinosis. *Biochem Biophys Res Commun.* 2000; 268:904–908. [PubMed: 10679303]
78. Lin L, Sohar I, Lackland H, Lobel P. The human CLN2 protein/tripeptidyl-peptidase I is a serine protease that autoactivates at acidic pH. *J Biol Chem.* 2001; 276:2249–2255. [PubMed: 11054422]
79. Guhaniyogi J, Sohar I, Das K, Stock AM, Lobel P. Crystal structure and autoactivation pathway of the precursor form of human tripeptidyl-peptidase I, the enzyme deficient in late infantile ceroid lipofuscinosis. *J Biol Chem.* 2009; 284:3985–3997. [PubMed: 19038967]
80. Golabek AA, Kida E, Walus M, Wujek P, Mehta P, Wisniewski KE. Biosynthesis, glycosylation, and enzymatic processing in vivo of human tripeptidyl-peptidase I. *J Biol Chem.* 2003; 278:7135–7145. [PubMed: 12488460]
81. Wlodawer A, Durell SR, Li M, Oyama H, Oda K, Dunn BM. A model of tripeptidyl-peptidase I (CLN2), a ubiquitous and highly conserved member of the sedolisin family of serine-carboxyl peptidases. *BMC Struct Biol.* 2003; 3:8. [PubMed: 14609438]
82. Tsiakas K, Steinfeld R, Storch S, Ezaki J, Lukacs Z, Kominami E, Kohlschutter A, Ullrich K, Braulke T. Mutation of the glycosylated asparagine residue 286 in human CLN2 protein results in loss of enzymatic activity. *Glycobiology.* 2004; 14:1C–5C. [PubMed: 14514713]
83. Steinfeld R, Steinke HB, Isbrandt D, Kohlschutter A, Gartner J. Mutations in classical late infantile neuronal ceroid lipofuscinosis disrupt transport of tripeptidyl-peptidase I to lysosomes. *Hum Mol Genet.* 2004; 13:2483–2491. [PubMed: 15317752]
84. Wujek P, Kida E, Walus M, Wisniewski KE, Golabek AA. N-glycosylation is crucial for folding, trafficking, and stability of human tripeptidyl-peptidase I. *J Biol Chem.* 2004; 279:12827–12839. [PubMed: 14702339]
85. Golabek AA, Dolzhanskaya N, Walus M, Wisniewski KE, Kida E. Prosegment of tripeptidyl peptidase I is a potent, slow-binding inhibitor of its cognate enzyme. *J Biol Chem.* 2008; 283:16497–16504. [PubMed: 18411270]
86. Steinfeld R, Fuhrmann JC, Gartner J. Detection of tripeptidyl peptidase I activity in living cells by fluorogenic substrates. *J Histochem Cytochem.* 2006; 54:991–996. [PubMed: 16782851]
87. Kurachi Y, Oka A, Itoh M, Mizuguchi M, Hayashi M, Takashima S. Distribution and development of CLN2 protein, the late-infantile neuronal ceroid lipofuscinosis gene product. *Acta Neuropathol.* 2001; 102:20–26. [PubMed: 11547947]
88. Sleat DE, El-Banna M, Sohar I, Kim KH, Dobrenis K, Walkley SU, Lobel P. Residual levels of tripeptidyl-peptidase I activity dramatically ameliorate disease in late-infantile neuronal ceroid lipofuscinosis. *Mol Genet Metab.* 2008; 94:222–233. [PubMed: 18343701]
89. Warburton MJ, Bernardini F. The specificity of lysosomal tripeptidyl peptidase-I determined by its action on angiotensin-II analogues. *FEBS Lett.* 2001; 500:145–148. [PubMed: 11445074]

90. Bernardini F, Warburton MJ. Lysosomal degradation of cholecystokinin-(29–33)-amide in mouse brain is dependent on tripeptidyl peptidase-I: implications for the degradation and storage of peptides in classical late-infantile neuronal ceroid lipofuscinosis. *Biochem J.* 2002; 366:521–529. [PubMed: 12038963]
91. Kopan S, Sivasubramaniam U, Warburton MJ. The lysosomal degradation of neuromedin B is dependent on tripeptidyl peptidase-I: evidence for the impairment of neuropeptide degradation in late-infantile neuronal ceroid lipofuscinosis. *Biochem Biophys Res Commun.* 2004; 319:58–65. [PubMed: 15158442]
92. Autefage H, Albinet V, Garcia V, Berges H, Nicolau ML, Therville N, Altie MF, Caillaud C, Levade T, Andrieu-Abadie N. Lysosomal serine protease CLN2 regulates tumor necrosis factor- α -mediated apoptosis in a Bid-dependent manner. *J Biol Chem.* 2009; 284:11507–11516. [PubMed: 19246452]
93. Ezaki J, Takeda-Ezaki M, Kominami E. Tripeptidyl peptidase I, the late infantile neuronal ceroid lipofuscinosis gene product, initiates the lysosomal degradation of subunit c of ATP synthase. *J Biochem.* 2000; 128:509–516. [PubMed: 10965052]
94. Tian Y, Sohar I, Taylor JW, Lobel P. Determination of the substrate specificity of tripeptidyl-peptidase I using combinatorial peptide libraries and development of improved fluorogenic substrates. *J Biol Chem.* 2006; 281:6559–6572. [PubMed: 16339154]
95. Vesa J, Chin MH, Oelgeschlager K, Isosomppi J, DellAngelica EC, Jalanko A, Peltonen L. Neuronal ceroid lipofuscinoses are connected at molecular level: interaction of CLN5 protein with CLN2 and CLN3. *Mol Biol Cell.* 2002; 13:2410–2420. [PubMed: 12134079]
96. Walus M, Kida E, Golabek AA. Functional consequences and rescue potential of pathogenic missense mutations in tripeptidyl peptidase I. *Hum Mutat.* 2010; 31:710–721. [PubMed: 20340139]
97. Savukoski M, Klockars T, Holmberg V, Santavuori P, Lander ES, Peltonen L. CLN5, a novel gene encoding a putative transmembrane protein mutated in Finnish variant late infantile neuronal ceroid lipofuscinosis. *Nat Genet.* 1998; 19:286–288. [PubMed: 9662406]
98. Isosomppi J, Vesa J, Jalanko A, Peltonen L. Lysosomal localization of the neuronal ceroid lipofuscinosis CLN5 protein. *Hum Mol Genet.* 2002; 11:885–891. [PubMed: 11971870]
99. Schmiedt ML, Bessa C, Heine C, Ribeiro MG, Jalanko A, Kyttala A. The neuronal ceroid lipofuscinosis protein CLN5: new insights into cellular maturation, transport, and consequences of mutations. *Hum Mutat.* 2010; 31:356–365. [PubMed: 20052765]
100. Holmberg V, Jalanko A, Isosomppi J, Fabritius AL, Peltonen L, Kopra O. The mouse ortholog of the neuronal ceroid lipofuscinosis CLN5 gene encodes a soluble lysosomal glyco-protein expressed in the developing brain. *Neurobiol Dis.* 2004; 16:29–40. [PubMed: 15207259]
101. Sleat DE, Ding L, Wang S, Zhao C, Wang Y, Xin W, Zheng H, Moore DF, Sims KB, Lobel P. Mass spectrometry-based protein profiling to determine the cause of lysosomal storage diseases of unknown etiology. *Mol Cell Proteomics.* 2009; 8:1708–1718. [PubMed: 19383612]
102. Lebrun AH, Storch S, Ruschendorf F, Schmiedt ML, Kyttala A, Mole SE, Kitzmuller C, Saar K, Mewasingh LD, Boda V, Kohlschutter A, Ullrich K, Bräulke T, Schulz A. Retention of lysosomal protein CLN5 in the endoplasmic reticulum causes neuronal ceroid lipofuscinosis in Asian sibship. *Hum Mutat.* 2009; 30:E651–E661. [PubMed: 19309691]
103. Sleat DE, Wang Y, Sohar I, Lackland H, Li Y, Li H, Zheng H, Lobel P. Identification and validation of mannose 6-phosphate glycoproteins in human plasma reveal a wide range of lysosomal and non-lysosomal proteins. *Mol Cell Proteomics.* 2006; 5:1942–1956. [PubMed: 16709564]
104. Vesa J, Peltonen L. Mutated genes in juvenile and variant late infantile neuronal ceroid lipofuscinoses encode lysosomal proteins. *Curr Mol Med.* 2002; 2:439–444. [PubMed: 12125809]
105. Lyly A, von Schantz C, Heine C, Schmiedt ML, Sipilä T, Jalanko A, Kyttala A. Novel interactions of CLN5 support molecular networking between Neuronal Ceroid Lipofuscinosis proteins. *BMC Cell Biol.* 2009; 10:83. [PubMed: 19941651]
106. Bessa C, Teixeira CA, Mangas M, Dias A, Sa Miranda MC, Guimaraes A, Ferreira JC, Canas N, Cabral P, Ribeiro MG. Two novel CLN5 mutations in a Portuguese patient with vLINCL:

- insights into molecular mechanisms of CLN5 deficiency. *Mol Genet Metab.* 2006; 89:245–253. [PubMed: 16814585]
107. Klockars T, Holmberg V, Savukoski M, Lander ES, Peltonen L. Transcript identification on the CLN5 region on chromosome 13q22. *Hum Genet.* 1999; 105:51–56. [PubMed: 10480355]
108. Klockars T, Savukoski M, Isosomppi J, Peltonen L. Positional cloning of the CLN5 gene defective in the Finnish variant of the LINCL. *Mol Genet Metab.* 1999; 66:324–328. [PubMed: 10191122]
109. Pineda-Trujillo N, Cornejo W, Carrizosa J, Wheeler RB, Munera S, Valencia A, Agudelo-Arango J, Cogollo A, Anderson G, Bedoya G, Mole SE, Ruiz-Linares A. A CLN5 mutation causing an atypical neuronal ceroid lipofuscinosis of juvenile onset. *Neurology.* 2005; 64:740–742. [PubMed: 15728307]
110. Cannelli N, Nardocci N, Cassandrini D, Morbin M, Aiello C, Bugiani M, Criscuolo L, Zara F, Striano P, Granata T, Bertini E, Simonati A, Santorelli FM. Revelation of a novel CLN5 mutation in early juvenile neuronal ceroid lipofuscinosis. *Neuropediatrics.* 2007; 38:46–49. [PubMed: 17607606]
111. Consortium BD. Isolation of a novel gene underlying Batten disease, CLN3. The International Batten Disease Consortium. *Cell.* 1995; 82:949–957. [PubMed: 7553855]
112. Chan CH, Mitchison HM, Pearce DA. Transcript and in silico analysis of CLN3 in juvenile neuronal ceroid lipofuscinosis and associated mouse models. *Hum Mol Genet.* 2008; 17:3332–3339. [PubMed: 18678598]
113. Margraf LR, Boriack RL, Routhet AA, Cuppen I, Alhilali L, Bennett CJ, Bennett MJ. Tissue expression and subcellular localization of CLN3, the Batten disease protein. *Mol Genet Metab.* 1999; 66:283–289. [PubMed: 10191116]
114. Golabek AA, Kaczmariski W, Kida E, Kaczmariski A, Michalewski MP, Wisniewski KE. Expression studies of CLN3 protein (battenin) in fusion with the green fluorescent protein in mammalian cells in vitro. *Mol Genet Metab.* 1999; 66:277–282. [PubMed: 10191115]
115. Kida E, Kaczmariski W, Golabek AA, Kaczmariski A, Michalewski M, Wisniewski KE. Analysis of intracellular distribution and trafficking of the CLN3 protein in fusion with the green fluorescent protein in vitro. *Mol Genet Metab.* 1999; 66:265–271. [PubMed: 10191113]
116. Kremmidiotis G, Lensink IL, Bilton RL, Woollatt E, Chataway TK, Sutherland GR, Callen DF. The Batten disease gene product (CLN3p) is a Golgi integral membrane protein. *Hum Mol Genet.* 1999; 8:523–531. [PubMed: 9949212]
117. Katz ML, Gao CL, Prabhakaram M, Shibuya H, Liu PC, Johnson GS. Immunohistochemical localization of the Batten disease (CLN3) protein in retina. *Invest Ophthalmol Vis Sci.* 1997; 38:2375–2386. [PubMed: 9344361]
118. Ezaki J, Takeda-Ezaki M, Koike M, Ohsawa Y, Taka H, Mineki R, Murayama K, Uchiyama Y, Ueno T, Kominami E. Characterization of Cln3p, the gene product responsible for juvenile neuronal ceroid lipofuscinosis, as a lysosomal integral membrane glycoprotein. *J Neurochem.* 2003; 87:1296–1308. [PubMed: 14622109]
119. Storch S, Pohl S, Quitsch A, Falley K, Bräulke T. C-terminal prenylation of the CLN3 membrane glycoprotein is required for efficient endosomal sorting to lysosomes. *Traffic.* 2007; 8:431–444. [PubMed: 17286803]
120. Luiro K, Kopra O, Lehtovirta M, Jalanko A. CLN3 protein is targeted to neuronal synapses but excluded from synaptic vesicles: new clues to Batten disease. *Hum Mol Genet.* 2001; 10:2123–2131. [PubMed: 11590129]
121. Jarvela I, Lehtovirta M, Tikkanen R, Kyttälä A, Jalanko A. Defective intracellular transport of CLN3 is the molecular basis of Batten disease (JNCL). *Hum Mol Genet.* 1999; 8:1091–1098. [PubMed: 10332042]
122. Phillips SN, Benedict JW, Weimer JM, Pearce DA. CLN3, the protein associated with batten disease: structure, function and localization. *J Neurosci Res.* 2005; 79:573–583. [PubMed: 15657902]
123. Storch S, Pohl S, Bräulke T. A dileucine motif and a cluster of acidic amino acids in the second cytoplasmic domain of the batten disease-related CLN3 protein are required for efficient lysosomal targeting. *J Biol Chem.* 2004; 279:53625–53634. [PubMed: 15469932]

124. Kytölä A, Yliannala K, Schu P, Jalanko A, Luzio JP. AP-1 and AP-3 facilitate lysosomal targeting of Batten disease protein CLN3 via its dileucine motif. *J Biol Chem.* 2005; 280:10277–10283. [PubMed: 15598649]
125. Kytölä A, Ihrke G, Vesa J, Schell MJ, Luzio JP. Two motifs target Batten disease protein CLN3 to lysosomes in transfected nonneuronal and neuronal cells. *Mol Biol Cell.* 2004; 15:1313–1323. [PubMed: 14699076]
126. Mao Q, Foster BJ, Xia H, Davidson BL. Membrane topology of CLN3, the protein underlying Batten disease. *FEBS Lett.* 2003; 541:40–46. [PubMed: 12706816]
127. Mao Q, Xia H, Davidson BL. Intracellular trafficking of CLN3, the protein underlying the childhood neurodegenerative disease, Batten disease. *FEBS Lett.* 2003; 555:351–357. [PubMed: 14644441]
128. Nugent T, Mole SE, Jones DT. The transmembrane topology of Batten disease protein CLN3 determined by consensus computational prediction constrained by experimental data. *FEBS Lett.* 2008; 582:1019–1024. [PubMed: 18314010]
129. Fields S, Song O. A novel genetic system to detect protein-protein interactions. *Nature.* 1989; 340:245–246. [PubMed: 2547163]
130. Uusi-Rauva K, Luiro K, Tanhuanpää K, Kopra O, Martin-Vasallo P, Kytölä A, Jalanko A. Novel interactions of CLN3 protein link Batten disease to dysregulation of fodrin-Na⁺, K⁺ ATPase complex. *Exp Cell Res.* 2008; 314:2895–2905. [PubMed: 18621045]
131. De Matteis MA, Morrow JS. Spectrin tethers and mesh in the biosynthetic pathway. *J Cell Sci.* 2000; 113:2331–2343. [PubMed: 10852813]
132. Bennett V, Baines AJ. Spectrin and ankyrin-based pathways: metazoan inventions for integrating cells into tissues. *Physiol Rev.* 2001; 81:1353–1392. [PubMed: 11427698]
133. Zimmer WE, Zhao Y, Sikorski AF, Critz SD, Sangerman J, Elferink LA, Xu XS, Goodman SR. The domain of brain beta-spectrin responsible for synaptic vesicle association is essential for synaptic transmission. *Brain Res.* 2000; 881:18–27. [PubMed: 11033089]
134. Nelson WJ, Hammerton RW. A membrane-cytoskeletal complex containing Na⁺, K⁺-ATPase, ankyrin, and fodrin in Madin-Darby canine kidney (MDCK) cells: implications for the biogenesis of epithelial cell polarity. *J Cell Biol.* 1989; 108:893–902. [PubMed: 2537837]
135. Kizhatil K, Sandhu NK, Peachey NS, Bennett V. Ankyrin-B is required for coordinated expression of beta-2-spectrin, the Na/K-ATPase and the Na/Ca exchanger in the inner segment of rod photoreceptors. *Exp Eye Res.* 2009; 88:57–64. [PubMed: 19007774]
136. Kaplan JH. Biochemistry of Na, K-ATPase. *Annu Rev Biochem.* 2002; 71:511–535. [PubMed: 12045105]
137. Geering K. Functional roles of Na, K-ATPase subunits. *Curr Opin Nephrol Hypertens.* 2008; 17:526–532. [PubMed: 18695395]
138. Crambert G, Geering K. FXYD proteins: new tissue-specific regulators of the ubiquitous Na, K-ATPase. *Sci STKE.* 2003; 2003:RE1. [PubMed: 12538882]
139. Blanco G, Mercer RW. Isozymes of the Na-K-ATPase: heterogeneity in structure, diversity in function. *Am J Physiol.* 1998; 275:F633–F650. [PubMed: 9815123]
140. Luiro K, Yliannala K, Ahtiainen L, Maunu H, Jarvela I, Kytölä A, Jalanko A. Interconnections of CLN3, Hook1 and Rab proteins link Batten disease to defects in the endocytic pathway. *Hum Mol Genet.* 2004; 13:3017–3027. [PubMed: 15471887]
141. Kramer H, Phistry M. Mutations in the *Drosophila* hook gene inhibit endocytosis of the boss transmembrane ligand into multivesicular bodies. *J Cell Biol.* 1996; 133:1205–1215. [PubMed: 8682859]
142. Walenta JH, Didier AJ, Liu X, Kramer H. The Golgi-associated hook3 protein is a member of a novel family of microtubule-binding proteins. *J Cell Biol.* 2001; 152:923–934. [PubMed: 11238449]
143. Kramer H, Phistry M. Genetic analysis of hook, a gene required for endocytic trafficking in *drosophila*. *Genetics.* 1999; 151:675–684. [PubMed: 9927460]
144. Weimer JM, Chattopadhyay S, Custer AW, Pearce DA. Elevation of Hook1 in a disease model of Batten disease does not affect a novel interaction between Ankyrin G and Hook1. *Biochem Biophys Res Commun.* 2005; 330:1176–1181. [PubMed: 15823567]

145. Geering K. Function of FXYD proteins, regulators of Na, K-ATPase. *J Bioenerg Biomembr.* 2005; 37:387–392. [PubMed: 16691470]
146. Rose EM, Koo JC, Antflick JE, Ahmed SM, Angers S, Hampson DR. Glutamate transporter coupling to Na, K-ATPase. *J Neurosci.* 2009; 29:8143–8155. [PubMed: 19553454]
147. Zhang D, Hou Q, Wang M, Lin A, Jarzylo L, Navis A, Raissi A, Liu F, Man HY. Na, K-ATPase activity regulates AMPA receptor turnover through proteasome-mediated proteolysis. *J Neurosci.* 2009; 29:4498–4511. [PubMed: 19357275]
148. Kovacs AD, Weimer JM, Pearce DA. Selectively increased sensitivity of cerebellar granule cells to AMPA receptor-mediated excitotoxicity in a mouse model of Batten disease. *Neurobiol Dis.* 2006; 22:575–585. [PubMed: 16483786]
149. Chattopadhyay S, Ito M, Cooper JD, Brooks AI, Curran TM, Powers JM, Pearce DA. An autoantibody inhibitory to glutamic acid decarboxylase in the neurodegenerative disorder Batten disease. *Hum Mol Genet.* 2002; 11:1421–1431. [PubMed: 12023984]
150. Luiro K, Kopra O, Blom T, Gentile M, Mitchison HM, Hovatta I, Tornquist K, Jalanko A. Batten disease (JNCL) is linked to disturbances in mitochondrial, cytoskeletal, and synaptic compartments. *J Neurosci Res.* 2006; 84:1124–1138. [PubMed: 16941499]
151. An WF, Bowlby MR, Betty M, Cao J, Ling HP, Mendoza G, Hinson JW, Mattsson KI, Strassle BW, Trimmer JS, Rhodes KJ. Modulation of A-type potassium channels by a family of calcium sensors. *Nature.* 2000; 403:553–556. [PubMed: 10676964]
152. Buxbaum JD, Choi EK, Luo Y, Lilliehook C, Crowley AC, Merriam DE, Wasco W. Calsenilin: a calcium-binding protein that interacts with the presenilins and regulates the levels of a presenilin fragment. *Nat Med.* 1998; 4:1177–1181. [PubMed: 9771752]
153. Lilliehook C, Chan S, Choi EK, Zaidi NF, Wasco W, Mattson MP, Buxbaum JD. Calsenilin enhances apoptosis by altering endoplasmic reticulum calcium signaling. *Mol Cell Neurosci.* 2002; 19:552–559. [PubMed: 11988022]
154. Choi EK, Zaidi NF, Miller JS, Crowley AC, Merriam DE, Lilliehook C, Buxbaum JD, Wasco W. Calsenilin is a substrate for caspase-3 that preferentially interacts with the familial Alzheimer's disease-associated C-terminal fragment of presenilin 2. *J Biol Chem.* 2001; 276:19197–19204. [PubMed: 11278424]
155. Jo DG, Kim MJ, Choi YH, Kim IK, Song YH, Woo HN, Chung CW, Jung YK. Pro-apoptotic function of calsenilin/DREAM/KChIP3. *FASEB J.* 2001; 15:589–591. [PubMed: 11259376]
156. Carrion AM, Link WA, Ledo F, Mellstrom B, Naranjo JR. DREAM is a Ca²⁺-regulated transcriptional repressor. *Nature.* 1999; 398:80–84. [PubMed: 10078534]
157. Zaidi NF, Thomson EE, Choi EK, Buxbaum JD, Wasco W. Intracellular calcium modulates the nuclear translocation of calsenilin. *J Neurochem.* 2004; 89:593–601. [PubMed: 15086516]
158. Chang JW, Choi H, Kim HJ, Jo DG, Jeon YJ, Noh JY, Park WJ, Jung YK. Neuronal vulnerability of CLN3 deletion to calcium-induced cytotoxicity is mediated by calsenilin. *Hum Mol Genet.* 2007; 16:317–326. [PubMed: 17189291]
159. Yu L, Sun C, Mendoza R, Wang J, Matayoshi ED, Hebert E, Pereda-Lopez A, Hajduk PJ, Olejniczak ET. Solution structure and calcium-binding properties of EF-hands 3 and 4 of calsenilin. *Protein Sci.* 2007; 16:2502–2509. [PubMed: 17962406]
160. Shibata R, Misonou H, Campomanes CR, Anderson AE, Schrader LA, Doliveira LC, Carroll KI, Sweatt JD, Rhodes KJ, Trimmer JS. A fundamental role for KChIPs in determining the molecular properties and trafficking of Kv4.2 potassium channels. *J Biol Chem.* 2003; 278:36445–36454. [PubMed: 12829703]
161. Wang K. Modulation by clamping: Kv4 and KChIP interactions. *Neurochem Res.* 2008; 33:1964–1969. [PubMed: 18415675]
162. Birnbaum SG, Varga AW, Yuan LL, Anderson AE, Sweatt JD, Schrader LA. Structure and function of Kv4-family transient potassium channels. *Physiol Rev.* 2004; 84:803–833. [PubMed: 15269337]
163. Cebolla B, Fernandez-Perez A, Perea G, Araque A, Vallejo M. DREAM mediates cAMP-dependent, Ca²⁺-induced stimulation of GFAP gene expression and regulates cortical astroglialogenesis. *J Neurosci.* 2008; 28:6703–6713. [PubMed: 18579744]

164. Pontikis CC, Cotman SL, MacDonald ME, Cooper JD. Thalamocortical neuron loss and localized astrocytosis in the Cln3Deltaex7/8 knock-in mouse model of Batten disease. *Neurobiol Dis.* 2005; 20:823–836. [PubMed: 16006136]
165. Francis R, McGrath G, Zhang J, Ruddy DA, Sym M, Apfeld J, Nicoll M, Maxwell M, Hai B, Ellis MC, Parks AL, Xu W, Li J, Gurney M, Myers RL, Himes CS, Hiebsch R, Ruble C, Nye JS, Curtis D. aph-1 and pen-2 are required for Notch pathway signaling, gamma-secretase cleavage of betaAPP, and presenilin protein accumulation. *Dev Cell.* 2002; 3:85–97. [PubMed: 12110170]
166. Lilliehook C, Bozdagi O, Yao J, Gomez-Ramirez M, Zaidi NF, Wasco W, Gandy S, Santucci AC, Haroutunian V, Huntley GW, Buxbaum JD. Altered Abeta formation and long-term potentiation in a calenilin knockout. *J Neurosci.* 2003; 23:9097–9106. [PubMed: 14534243]
167. Lathia JD, Mattson MP, Cheng A. Notch: from neural development to neurological disorders. *J Neurochem.* 2008; 107:1471–1481. [PubMed: 19094054]
168. Weimer JM, Benedict JW, Getty AL, Pontikis CC, Lim MJ, Cooper JD, Pearce DA. Cerebellar defects in a mouse model of juvenile neuronal ceroid lipofuscinosis. *Brain Res.* 2009; 1266:93–107. [PubMed: 19230832]
169. Solecki DJ, Liu XL, Tomoda T, Fang Y, Hatten ME. Activated Notch2 signaling inhibits differentiation of cerebellar granule neuron precursors by maintaining proliferation. *Neuron.* 2001; 31:557–568. [PubMed: 11545715]
170. Tuxworth RI, Vivancos V, O'Hare MB, Tear G. Interactions between the juvenile Batten disease gene, CLN3, and the Notch and JNK signalling pathways. *Hum Mol Genet.* 2009; 18:667–678. [PubMed: 19028667]
171. Kataoka N, Diem MD, Kim VN, Yong J, Dreyfuss G. Magoh, a human homolog of *Drosophila* mago nashi protein, is a component of the splicing-dependent exon-exon junction complex. *EMBO J.* 2001; 20:6424–6433. [PubMed: 11707413]
172. Micklem DR, Dasgupta R, Elliott H, Gergely F, Davidson C, Brand A, Gonzalez-Reyes A, St Johnston D. The mago nashi gene is required for the polarisation of the oocyte and the formation of perpendicular axes in *Drosophila*. *Curr Biol.* 1997; 7:468–478. [PubMed: 9210377]
173. Vitiello SP, Benedict JW, Padilla-Lopez S, Pearce DA. Interaction between Sdo1p and Btn1p in the *Saccharomyces cerevisiae* model for Batten disease. *Hum Mol Genet.* 2010; 19:931–942. [PubMed: 20015955]
174. Boocock GR, Marit MR, Rommens JM. Phylogeny, sequence conservation, and functional complementation of the SBDS protein family. *Genomics.* 2006; 87:758–771. [PubMed: 16529906]
175. Menne TF, Goyenechea B, Sanchez-Puig N, Wong CC, Tonkin LM, Ancliff PJ, Brost RL, Costanzo M, Boone C, Warren AJ. The Shwachman-Bodian-Diamond syndrome protein mediates translational activation of ribosomes in yeast. *Nat Genet.* 2007; 39:486–495. [PubMed: 17353896]
176. Luz JS, Georg RC, Gomes CH, Machado-Santelli GM, Oliveira CC. Sdo1p, the yeast orthologue of Shwachman-Bodian-Diamond syndrome protein, binds RNA and interacts with nuclear rRNA-processing factors. *Yeast.* 2009; 26:287–298. [PubMed: 19350533]
177. Ball HL, Zhang B, Riches JJ, Gandhi R, Li J, Rommens JM, Myers JS. Shwachman-Bodian Diamond syndrome is a multi-functional protein implicated in cellular stress responses. *Hum Mol Genet.* 2009; 18:3684–3695. [PubMed: 19602484]
178. Boocock GR, Morrison JA, Popovic M, Richards N, Ellis L, Durie PR, Rommens JM. Mutations in SBDS are associated with Shwachman-Diamond syndrome. *Nat Genet.* 2003; 33:97–101. [PubMed: 12496757]
179. Toiviainen-Salo S, Makitie O, Mannerkoski M, Hamalainen J, Valanne L, Autti T. Shwachman-Diamond syndrome is associated with structural brain alterations on MRI. *Am J Med Genet A.* 2008; 146A:1558–1564. [PubMed: 18478597]
180. Boriack RL, Bennett MJ. CLN-3 protein is expressed in the pancreatic somatostatin-secreting delta cells. *Eur J Paediatr Neurol.* 2001; 5(Suppl A):99–102. [PubMed: 11589017]
181. Wessels D, Srikantha T, Yi S, Kuhl S, Aravind L, Soll DR. The Shwachman-Bodian-Diamond syndrome gene encodes an RNA-binding protein that localizes to the pseudopod of *Dictyostelium amoebae* during chemotaxis. *J Cell Sci.* 2006; 119:370–379. [PubMed: 16410554]

182. Stepanovic V, Wessels D, Goldman FD, Geiger J, Soll DR. The chemotaxis defect of Shwachman-Diamond Syndrome leukocytes. *Cell Motil Cytoskeleton*. 2004; 57:158–174. [PubMed: 14743349]
183. Vicente-Manzanares M, Ma X, Adelstein RS, Horwitz AR. Non-muscle myosin II takes centre stage in cell adhesion and migration. *Nat Rev Mol Cell Biol*. 2009; 10:778–790. [PubMed: 19851336]
184. Sharp JD, Wheeler RB, Lake BD, Fox M, Gardiner RM, Williams RE. Genetic and physical mapping of the CLN6 gene on chromosome 15q21–23. *Mol Genet Metab*. 1999; 66:329–331. [PubMed: 10191123]
185. Gao H, Boustany RM, Espinola JA, Cotman SL, Srinidhi L, Antonellis KA, Gillis T, Qin X, Liu S, Donahue LR, Bronson RT, Faust JR, Stout D, Haines JL, Lerner TJ, MacDonald ME. Mutations in a novel CLN6-encoded transmembrane protein cause variant neuronal ceroid lipofuscinosis in man and mouse. *Am J Hum Genet*. 2002; 70:324–335. [PubMed: 11791207]
186. Heine C, Koch B, Storch S, Kohlschutter A, Palmer DN, Bräulke T. Defective endoplasmic reticulum-resident membrane protein CLN6 affects lysosomal degradation of endocytosed arylsulfatase A. *J Biol Chem*. 2004; 279:22347–22352. [PubMed: 15010453]
187. Mole SE, Michaux G, Codlin S, Wheeler RB, Sharp JD, Cutler DF. CLN6, which is associated with a lysosomal storage disease, is an endoplasmic reticulum protein. *Exp Cell Res*. 2004; 298:399–406. [PubMed: 15265688]
188. Heine C, Quitsch A, Storch S, Martin Y, Lonka L, Lehesjoki AE, Mole SE, Bräulke T. Topology and endoplasmic reticulum retention signals of the lysosomal storage disease-related membrane protein CLN6. *Mol Membr Biol*. 2007; 24:74–87. [PubMed: 17453415]
189. Benedict JW, Getty AL, Wishart TM, Gillingwater TH, Pearce DA. Protein product of CLN6 gene responsible for variant late-onset infantile neuronal ceroid lipofuscinosis interacts with CRMP-2. *J Neurosci Res*. 2009; 87:2157–2166. [PubMed: 19235893]
190. Inagaki N, Chihara K, Arimura N, Menager C, Kawano Y, Matsuo N, Nishimura T, Amano M, Kaibuchi K. CRMP-2 induces axons in cultured hippocampal neurons. *Nat Neurosci*. 2001; 4:781–782. [PubMed: 11477421]
191. Arimura N, Menager C, Fukata Y, Kaibuchi K. Role of CRMP-2 in neuronal polarity. *J Neurobiol*. 2004; 58:34–47. [PubMed: 14598368]
192. Yoshimura T, Kawano Y, Arimura N, Kawabata S, Kikuchi A, Kaibuchi K. GSK-3 β regulates phosphorylation of CRMP-2 and neuronal polarity. *Cell*. 2005; 120:137–149. [PubMed: 15652488]
193. Nishimura T, Fukata Y, Kato K, Yamaguchi T, Matsuura Y, Kamiguchi H, Kaibuchi K. CRMP-2 regulates polarized Numb-mediated endocytosis for axon growth. *Nat Cell Biol*. 2003; 5:819–826. [PubMed: 12942088]
194. Fukata Y, Itoh TJ, Kimura T, Menager C, Nishimura T, Shir-omizu T, Watanabe H, Inagaki N, Iwamatsu A, Hotani H, Kaibuchi K. CRMP-2 binds to tubulin heterodimers to promote microtubule assembly. *Nat Cell Biol*. 2002; 4:583–591. [PubMed: 12134159]
195. Kawano Y, Yoshimura T, Tsuboi D, Kawabata S, Kaneko-Kawano T, Shirataki H, Takenawa T, Kaibuchi K. CRMP-2 is involved in kinesin-1-dependent transport of the Sra-1/WAVE1 complex and axon formation. *Mol Cell Biol*. 2005; 25:9920–9935. [PubMed: 16260607]
196. Wheeler RB, Sharp JD, Mitchell WA, Bate SL, Williams RE, Lake BD, Gardiner RM. A new locus for variant late infantile neuronal ceroid lipofuscinosis-CLN7. *Mol Genet Metab*. 1999; 66:337–338. [PubMed: 10191125]
197. Mitchell WA, Wheeler RB, Sharp JD, Bate SL, Gardiner RM, Ranta US, Lonka L, Williams RE, Lehesjoki AE, Mole SE. Turkish variant late infantile neuronal ceroid lipofuscinosis (CLN7) may be allelic to CLN8. *Eur J Paediatr Neurol*. 2001; 5(Suppl A):21–27. [PubMed: 11589000]
198. Kousi M, Siintola E, Dvorakova L, Vlaskova H, Turnbull J, Topcu M, Yuksel D, Gokben S, Minassian BA, Elleder M, Mole SE, Lehesjoki AE. Mutations in CLN7/MFSD8 are a common cause of variant late-infantile neuronal ceroid lipofuscinosis. *Brain*. 2009; 132:810–819. [PubMed: 19201763]
199. Aiello C, Terracciano A, Simonati A, Discepoli G, Cannelli N, Claps D, Crow YJ, Bianchi M, Kitzmuller C, Longo D, Tavoni A, Franzoni E, Tessa A, Veneselli E, Boldrini R, Filocamo M,

- Williams RE, Bertini ES, Biancheri R, Carrozzo R, Mole SE, Santorelli FM. Mutations in MFSD8/CLN7 are a frequent cause of variant-late infantile neuronal ceroid lipofuscinosis. *Hum Mutat.* 2009; 30:E530–E540. [PubMed: 19177532]
200. Siintola E, Topcu M, Aula N, Lohi H, Minassian BA, Paterson AD, Liu XQ, Wilson C, Lahtinen U, Anttonen AK, Lehesjoki AE. The novel neuronal ceroid lipofuscinosis gene MFSD8 encodes a putative lysosomal transporter. *Am J Hum Genet.* 2007; 81:136–146. [PubMed: 17564970]
201. Steenhuis P, Herder S, Gelis S, Bräulke T, Storch S. Lysosomal targeting of the CLN7 membrane glycoprotein and transport via the plasma membrane require a dileucine motif. *Traffic.* 2010;10.1111/j.1600-0854.2010.01073.x
202. Pao SS, Paulsen IT, Saier MH Jr. Major facilitator superfamily. *Microbiol Mol Biol Rev.* 1998; 62:1–34. [PubMed: 9529885]
203. Ranta S, Topcu M, Tegelberg S, Tan H, Ustubutun A, Saatci I, Dufke A, Enders H, Pohl K, Alembik Y, Mitchell WA, Mole SE, Lehesjoki AE. Variant late infantile neuronal ceroid lipofuscinosis in a subset of Turkish patients is allelic to Northern epilepsy. *Hum Mutat.* 2004; 23:300–305. [PubMed: 15024724]
204. Ranta S, Zhang Y, Ross B, Lonka L, Takkunen E, Messer A, Sharp J, Wheeler R, Kusumi K, Mole S, Liu W, Soares MB, Bonaldo MF, Hirvasniemi A, de la Chapelle A, Gilliam TC, Lehesjoki AE. The neuronal ceroid lipofuscinoses in human EPMR and mnd mutant mice are associated with mutations in CLN8. *Nat Genet.* 1999; 23:233–236. [PubMed: 10508524]
205. Reinhardt K, Grapp M, Schlachter K, Bruck W, Gartner J, Steinfeld R. Novel CLN8 mutations confirm the clinical and ethnic diversity of late infantile neuronal ceroid lipofuscinosis. *Clin Genet.* 2010; 77:79–85. [PubMed: 19807737]
206. Cannelli N, Cassandrini D, Bertini E, Striano P, Fusco L, Gaggero R, Specchio N, Biancheri R, Vigeveno F, Bruno C, Simonati A, Zara F, Santorelli FM. Novel mutations in CLN8 in Italian variant late infantile neuronal ceroid lipofuscinosis: another genetic hit in the Mediterranean. *Neurogenetics.* 2006; 7:111–117. [PubMed: 16570191]
207. Vantaggiato C, Redaelli F, Falcone S, Perrotta C, Tonelli A, Bondioni S, Morbin M, Riva D, Saletti V, Bonaglia MC, Giorda R, Bresolin N, Clementi E, Bassi MT. A novel CLN8 mutation in late-infantile-onset neuronal ceroid lipofuscinosis (LINCL) reveals aspects of CLN8 neurobiological function. *Hum Mutat.* 2009; 30:1104–1116. [PubMed: 19431184]
208. Bronson RT, Donahue LR, Johnson KR, Tanner A, Lane PW, Faust JR. Neuronal ceroid lipofuscinosis (nclf), a new disorder of the mouse linked to chromosome 9. *Am J Med Genet.* 1998; 77:289–297. [PubMed: 9600738]
209. Lonka L, Kytälä A, Ranta S, Jalanko A, Lehesjoki AE. The neuronal ceroid lipofuscinosis CLN8 membrane protein is a resident of the endoplasmic reticulum. *Hum Mol Genet.* 2000; 9:1691–1697. [PubMed: 10861296]
210. Lonka L, Salonen T, Siintola E, Kopra O, Lehesjoki AE, Jalanko A. Localization of wild-type and mutant neuronal ceroid lipofuscinosis CLN8 proteins in non-neuronal and neuronal cells. *J Neurosci Res.* 2004; 76:862–871. [PubMed: 15160397]
211. D’Mello NP, Childress AM, Franklin DS, Kale SP, Pinswasdi C, Jazwinski SM. Cloning and characterization of LAG1, a longevity-assurance gene in yeast. *J Biol Chem.* 1994; 269:15451–15459. [PubMed: 8195187]
212. Hegde RS, Voigt S, Rapoport TA, Lingappa VR. TRAM regulates the exposure of nascent secretory proteins to the cytosol during translocation into the endoplasmic reticulum. *Cell.* 1998; 92:621–631. [PubMed: 9506517]
213. Winter E, Ponting CP. TRAM, LAG1 and CLN8: members of a novel family of lipid-sensing domains? *Trends Biochem Sci.* 2002; 27:381–383. [PubMed: 12151215]
214. Hermansson M, Kakela R, Berghall M, Lehesjoki AE, Somerharju P, Lahtinen U. Mass spectrometric analysis reveals changes in phospholipid, neutral sphingolipid and sulfatide molecular species in progressive epilepsy with mental retardation, EPMR, brain: a case study. *J Neurochem.* 2005; 95:609–617. [PubMed: 16086686]
215. Vance JE, Stone SJ, Faust JR. Abnormalities in mitochondria-associated membranes and phospholipid biosynthetic enzymes in the mnd/mnd mouse model of neuronal ceroid lipofuscinosis. *Biochim Biophys Acta.* 1997; 1344:286–299. [PubMed: 9059519]

216. Zhong NA, Moroziewicz DN, Ju W, Wisniewski KE, Jurkiewicz A, Brown WT. CLN-encoded proteins do not interact with each other. *Neurogenetics*. 2000; 3:41–44. [PubMed: 11085596]
217. Persaud-Sawin DA, Mousallem T, Wang C, Zucker A, Kominami E, Boustany RM. Neuronal ceroid lipofuscinosis: a common pathway? *Pediatr Res*. 2007; 61:146–152. [PubMed: 17237713]
218. von Schantz C, Saharinen J, Kopra O, Cooper JD, Gentile M, Hovatta I, Peltonen L, Jalanko A. Brain gene expression profiles of Cln1 and Cln5 deficient mice unravels common molecular pathways underlying neuronal degeneration in NCL diseases. *BMC Genomics*. 2008; 9:146. [PubMed: 18371231]
219. Lonka L, Aalto A, Kopra O, Kuronen M, Kokaia Z, Saarma M, Lehesjoki AE. The neuronal ceroid lipofuscinosis Cln8 gene expression is developmentally regulated in mouse brain and up-regulated in the hippocampal kindling model of epilepsy. *BMC Neurosci*. 2005; 6:27. [PubMed: 15826318]
220. Getty AL, Benedict JW, Pearce DA. A novel interaction of CLN3 with nonmuscle myosin-IIb and an associated cell-motility defect in *Cln3^{-/-}*. *Exp Cell Res*. 2010 (submitted).

Fig. 1.

The interactions and locations of NCL proteins. **a** Soluble NCL proteins with known enzymatic activity: *PPT1*, *TPP1*, and cathepsin D (*CathD*), are localized to the lysosome and interact with their substrates in the lysosome lumen. **b** *CLN3* has been reported to localize to several subcellular locations and, as described in the text for the purposes of this review, is depicted in the lysosomal membrane, and interacts with several proteins including proteins at the cell periphery. *CLN3* interacts with *SBDS*, *calsenilin*, and *myosin-IIB* through the C-terminus, and the fodrin- Na^+-K^+ -ATPase complex through a cytosolic loop. *CLN3* most likely does not interact with all of these proteins at the same time, but rather these interactions are probably dynamic. **c** *CLN5* is a highly glycosylated protein is localized to

the lysosome. It has potential interactions with NCL proteins and has been shown to interact with *CLN6* and *CLN8*, potentially in the ER. Interactions of CLN5 and PPT1 have been described with the F₁-complex of the ATP-Synthase, which may occur during mitochondrial degradation. **d** *CLN6* and *CLN8* are both transmembrane proteins that reside in the ER, and CLN6 interacts with *CRMP-2*. **e** *CLN7*, a putative transporter (MFSD8) resides in the lysosomal membrane, but the interactions or function of CLN7/MFSD8 has not been elucidated. A representative lysosome (*red*) is highlighted for each NCL protein, though these lysosomal proteins probably exist together in many lysosomes

Table 1

Biochemical properties of the NCL proteins

NCL onset	Gene	Protein	Amino acids and size	Solubility and topology	Posttranslational modifications	Localization	Interactions	Function
Congenital	<i>CLN10</i> <i>CTSD</i>	Cathepsin D	412 aa 45 kDa	Soluble	Cleaved pro-enzyme Glycosylated	Lysosome Secreted	Many substrates	Aspartic protease Lipid homeostasis
Infantile	<i>CLN1</i>	PPT1	306 aa 34 kDa	Soluble	Glycosylated	Lysosome; Synaptic vesicles Lipid rafts	Substrates F1 complex of ATP synthase	Thioesterase of fatty acyl chains (14–18 carbons) such as palmitate residues
Late-Infantile	<i>CLN2</i>	TPP1	563 aa 46 kDa	Soluble	Cleaved pro-enzyme Glycosylated	Lysosome	Substrates e.g. subunit C of ATP Synthase neuromedin B Bid	Serine protease, cleaves N-terminal tripeptides
Juvenile	<i>CLN3</i>	CLN3	438 aa ~47 kDa	Membrane 6-TM domains both termini in cytosol	Glycosylated Phosphorylated Farnesylated	Lysosome Endosome Golgi Synaptosomes Lipid Rafts	Na–K-ATPase, Fodrin Hook1 Calsenilin/DREAM/KChIP3 SBDS Myosin-IIB	Unknown
Finnish LINCL	<i>CLN5</i>	CLN5	358 aa 55 kDa	Soluble	Glycosylated	Lysosome ER/Golgi?	Proposed: PPT1, TPP1, CLN3 CLN6, CLN8 F1 complex of ATP Synthase	Unknown
vLINCL	<i>CLN6</i>	CLN6	311 aa 36 kDa	Membrane 7-TM domains N-terminus in cytoplasm C-terminus in ER lumen	None Known	ER	CRMP-2 Dimerizes	Unknown Neuronal Maturation and Polarity?
vLINCL	<i>CLN7/MFSD8</i>	CLN7 MFSD8	518 aa 100 and 70 kDa	Membrane 12-TM domains	Glycosylated	Lysosome Plasma membrane	None shown	Transporter
EPMR vLINCL	<i>CLN8</i>	CLN8	28 6aa 33 kDa	Membrane 4–6 TM domains	None known	ER/ERGIC Neuronal processes	None shown	Unknown Lipid Binding?

Table 2

NCL gene expression in mouse central nervous system

Gene	E11	E15	P7	P42
<i>CLN10/CTSD</i>	+++	+++	+++	++
<i>CLN1</i>	n/a	n/a	n/a	n/a
<i>CLN2</i>	+	+++	++	n/a
<i>CLN3</i>	+	+++	++	++
<i>CLN5</i>	–	+	–	n/a
<i>CLN6</i>	+	++	+++	++
<i>CLN7/MFSD8</i>	n/a	n/a	n/a	n/a
<i>CLN8</i>	+	+	+	^a

Relative expression levels indicated as: *n/a* not available in database, – no expression, + low expression, ++ moderate expression, +++ high expression, as determined qualitatively by in situ on the Brain Gene Expression Map (stjudebgem.org).

^a *Cln8* expression is seen in postnatal brains in the cortex and hippocampus [219]